

Best Available Copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :	A2	(11) International Publication Number: WO 00/07627
A61K 47/10, 47/14, 47/34, 7/06		(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/US99/17387

(22) International Filing Date: 2 August 1999 (02.08.99)

(30) Priority Data:
60/095,289 4 August 1998 (04.08.98) US
09/363,412 23 July 1999 (23.07.99) US

(71) Applicant (for all designated States except US): JOHNSON & JOHNSON CONSUMER COMPANIES, INC. [US/US]; Grandview Road, Skillman, NJ 08558 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NIEMIEC, Susan, M. [US/US]; 1808 Waterford Road, Yardley, PA 19067 (US). WANG, Jonas, C., T. [US/US]; 23 Ellsworth Drive, Robbinsville, NJ 08691 (US). WISNIEWSKI, Stephen, J. [US/US]; 6820 Pt. Pleasant Pike, Doylestown, PA 18901 (US). STENN, Kurt, S. [US/US]; 47 Bayard Lane, Princeton, NJ 08540 (US). LU, Gwang, Wei [CN/US]; 10 Heather Court, Plainsboro, NJ 08536 (US).

(74) Agents: CIAMPORCERO, Audley, A. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).

(54) Title: TOPICAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

(57) Abstract

This invention relates to a method for enhancing the transmembrane penetration of benefit agents using a certain non-ionic lipid/surfactant-containing formulation as an enhancing agent, and the compositions used therein. Various active agents, such as anti-dandruff agents, hair growth agents, hair inhibitor agents, anti-acne agents, anti-aging agents, depilatory agents, and depigmentation agents, may be effectively delivered into the skin, hair follicles and sebaceous glands using the compositions of the present invention.

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	République of Moldova	TG	Togo
BI	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BR	Burkina Faso	GR	Greece	ML	Malí	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TI	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TOPICAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

Cross-Reference to Related Application

10 This Application claims the benefit of United States Serial Number 60/095,289 filed on 4 August 1998, which is incorporated herein in its entirety.

Field of the Invention

15 This invention relates to a method for the topical delivery of active agents (e.g., drugs), and compositions used therein. More specifically, this invention relates to a method for enhancing the transmembrane penetration of benefit agents using a certain non-ionic lipid/surfactant-containing formulation as an enhancing agent, and the compositions used therein.

Background of the Invention

20 The topical delivery of an active agent, such as a drug, from a given vehicle is a multistep process which involves; 1) the dissolution, diffusion and/or release of the agent from the vehicle; 2) the transport of the agent to the absorption site; 3) the permeation of the agent through the limiting barrier at the target site; and eventually 4) the elimination of the agent via blood circulation. In order for an active agent to be effectively transported into the 25 epidermal absorption site, the agent must be present at the skin/vehicle interface, be soluble in the available surrounding fluids, and be capable of diffusing down the hair follicle or partitioning into the stratum corneum.

30 It is well known in the art that the skin presents a formidable barrier to the penetration of active agents due to the presence of the stratum corneum, which is the outermost layer of the skin composed of close packed dead keratinized cells. Thus, the ability of a substance, which is applied to the skin surface, to penetrate through the skin is inversely related to the thickness of the stratum corneum layer.

35 One known method for enabling the penetration of active agents through the skin is via topical administration. One shortcoming associated with this method is that some active agents, in particular those having a relatively high molecular weight, are not easily absorbed by the skin.

40 Many methods for enhancing the local penetration of pharmacologically active agents are known in the art. In one approach, surface active agents are included in the pharmacologically active agent-containing formulation. However, this addition of surface active agents results in only a slight to moderate enhancement of permeability at the expense of damaging the barrier skin tissue. See, e.g., Zatz, J.L., *Modification of Skin Permeation by Surface-Active Agents in Skin Permeation Fundamentals and Application*,

5 149-162 (1993); and Barry, B.W., "Properties That Influence Percutaneous Absorption in Dermatological Formulations," *Percutaneous Absorption*, 127-233 (1983). (Addition of "penetration enhancers" increases the permeability of the stratum corneum by disrupting the lipid organization therein.)

10 Traditionally, the prime pathway for the topical delivery of active agents across the skin was thought to be through intercellular routes and transcellular routes of the stratum corneum. However, alternative means such as via appendageal transport, i.e., follicular transport, is gaining more acceptance in the scientific community. See, e.g., Schaefer, H., et al. *Follicular Penetration in Prediction of Percutaneous Penetration: Methods, Measurements, and Modeling*, 163-173 (1990) (optimum size for uptake of micro-beads by the skin appendages is between 5-7 μ m). Due to the comparatively lower barrier resistance of the follicles, follicular transport has particular relevance for enabling the delivery of active agents having low diffusion constants, varying solubility characteristics, and/or varying size characteristics.

15

20 One of the diseases associated with the hair follicle is androgenetic alopecia ("AGA"), which is the most common cause of hair loss in both men and women and is identifiable by the loss of hair over the vertex of the scalp. Commonly known treatments for AGA include hair follicle transplants, topical therapies, and orally prescribed anti-androgens. See, e.g., J.L. Roberts, "Androgenetic Alopecia in Men and Women: An Overview of Cause and Treatment," 9(6) *Dermatology Nursing* 379-386 (1997).

25 Minoxidil is a drug that is often prescribed for the treatment of AGA. Disadvantageously, clinical trials have shown that the topical application of a 2% minoxidil solution to patients experiencing hair loss results stimulated dense hair regrowth in only less than about 5% of the patients and moderate hair regrowth in only about 30% of the patients. See e.g., E.A. Olsen, et al., "Topical Minoxidil in Early Male Pattern Baldness," 13, *J. Amer. Acad. Derm.* 185-192 (1985); and J. Roberts, "Androgenetic Alopecia: Treatment With Topical Minoxidil," 16(3) *J. Amer. Acad. Derm.* 705-710 (1987). Moreover, treatments with topical solutions of minoxidil require multiple daily applications, which is not only inconvenient but also expensive.

30

35 One known method for the topical administration of minoxidil is via a mousse formulation containing a cellulose derivative film former as disclosed in PCT Patent Application No. PCT/US98/17387. Unfortunately, the cellulose derivative inhibits the diffusion of the minoxidil from the vehicle, which thereby leads to decreased efficacy of the minoxidil.

5 Various delivery systems are also known in the art for topically delivering anti-acne agents, anti-aging agents, and depigmentation agents to the epidermis and/or dermis. In one method, high levels of alcohol are used to facilitate the delivery of the agent. However, such alcohols disadvantageously tend to extract lipids from the skin surface, which leads to excessively dry skin and irritation. See, e.g. Zatz, J.L. Modification of Skin Permeation by
10 Solvents in Skin Permeation Fundamentals and Application, 146-148 (1993).

15 It is therefore an object of this invention to provide improved compositions for enabling the topical delivery of pharmacologically active substances without significant adverse side effects on the skin or body membranes. It is also a further object to provide improved compositions for enabling the topical delivery of difficult-to-absorb agents for localized action. It is a further objective to provide an economic, effective topical treatment for hair loss that is convenient to apply. It is yet a further objective to provide improved compositions for enabling the topical delivery of anti-dandruff, depilatory, anti-acne, anti-aging, and depigmentation active agents into the skin.

20 Summary of the Invention

In accordance with the present invention, we have found a composition for enhancing the topical delivery of benefit agents comprising, consisting essentially of, or consisting of, based upon the total weight of the composition,:

25 A. from about 1 percent to about 10 percent of a nonionic lipid selected from
i. glyceryl monoesters having a fatty acid chain containing from about 3 to about 50 carbon atoms;
ii. glyceryl diesters having a fatty acid chain containing from about 5 carbon atoms to about 25 carbon atoms;
iii. alkoxylated alcohols alkoxylated with ethylene oxide or propylene oxide;
30 iv. alkoxylated alkyl phenols alkoxylated with ethylene oxide or propylene oxide;
v. alkoxylated acids alkoxylated with ethylene oxide or propylene oxide;
vi. alkoxylated amides alkoxylated with ethylene oxide or propylene oxide;
vii. alkoxylated sugar derivatives alkoxylated with ethylene oxide or
viii. alkoxylated derivatives of natural oils or waxes alkoxylated with ethylene oxide or propylene oxide;
35 ix. polyoxyethylene polyoxypropylene block copolymers alkoxylated with ethylene oxide or propylene oxide;

5 x. polyoxyethylene fatty ethers having a fatty acid chain containing from
about 10 carbon atoms to about 18 carbon atoms;

10 xi. steroids;

15 xii. fatty acid esters of alcohols where the fatty acid is straight or branched
chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol
is straight or branched chain having 1 to 10 carbon atoms; or

20 xiii. mixtures thereof;

25 B. from about 75 percent to about 98 percent of a vehicle solution comprised of:
1) a first vehicle component comprised of water or a mixture of water and a
hydrophilic compound; and

30 2) a second vehicle component comprised of an alcohol, a polyol, or
mixtures thereof; and

35 C. an effective amount of the benefit agent(s).

40 In another embodiment of the present invention, we have found a topical delivery
system for active agents comprising, consisting of, or consisting essentially of, based upon
the total weight of the delivery system,

45 A. from about 0.5 percent to about 10 percent, and preferably from about 0.5
percent to about 5 percent, of a nonionic lipid selected from

50 i. glyceryl monoesters having a fatty acid chain containing from about 3 to
about 50 carbon atoms;

55 ii. glyceryl diesters having a fatty acid chain containing from about 5 carbon
atoms to about 25 carbon atoms;

60 iii. alkoxylated alcohols alkoxylated with ethylene oxide or propylene oxide;

65 iv. alkoxylated alkyl phenols alkoxylated with ethylene oxide or propylene
oxide;

70 v. alkoxylated acids alkoxylated with ethylene oxide or propylene oxide;

75 vi. alkoxylated amides alkoxylated with ethylene oxide or propylene oxide;

80 vii. alkoxylated sugar derivatives alkoxylated with ethylene oxide or
propylene oxide;

85 viii. alkoxylated derivatives of natural oils or waxes alkoxylated with
ethylene oxide or propylene oxide;

90 ix. polyoxyethylene fatty acids having a fatty acid chain containing from about 10 to
about 20 carbon atoms and the alcohol having 1 to 10 carbon atoms alkoxylated with
ethylene oxide or propylene oxide;

95 x. polyoxyethylene fatty ethers having a fatty acid chain containing from about 10 carbon atoms to about 18 carbon atoms;

xi. steroids;

xii. fatty acid esters of alcohols where the fatty acid is straight or branched chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or branched chain having 1 to 10 carbon atoms; or

xiii. mixtures thereof; and

10 B. from about 74 percent to about 99.5 percent of a vehicle solution comprised of:

1) a first vehicle component comprised of water or a mixture of water and a hydrophilic compound; and

2) a second vehicle component comprised of an alcohol, a polyol, or mixtures thereof.

15 In another embodiment of the present invention, we have found a method for enhancing the topical delivery of benefit agents which comprises, consists of, or consists essentially of topically administering to a human or animal the above-described composition.

In yet another embodiment of the present invention we have found a method for treating hair loss comprising, consisting of, and/or consisting essentially of topically applying to skin at a desired area for hair induction the above-described composition, wherein the benefit agent is a hair loss treatment agent. In yet another embodiment of the present invention we have found a method for treating the effects of aging comprising, consisting of, and/or consisting essentially of topically applying to skin at a desired area a composition similar to that described with hair growth, but wherein the benefit agent is an anti-aging active agent. In yet

20 25 another embodiment of the present invention we have found a method for treating acne comprising, consisting of, and/or consisting essentially of topically applying to skin at a desired area for treatment a composition similar to that described with respect to anti-aging, but wherein the benefit agent is an anti-acne active agent. In yet another embodiment of the present invention we have found a method for inducing hair loss comprising, consisting of, and/or consisting essentially of topically applying to skin at a desired area for treatment a composition similar to that described with respect to anti-aging, but wherein the benefit agent is a hair loss inducing active agent. In yet another embodiment of the present invention we have found a method for depigmenting the skin comprising, consisting of, and/or consisting essentially of topically applying to skin at a desired area for treatment a composition similar to that described with respect to anti-aging, but wherein the benefit agent is a depigmentation active agent.

30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

5 provide an effective, economical method for treating hair loss resulting from alopecia. In addition, when the composition contains an effective amount of anti-acne agent, the composition and methods of this invention provide an effective, economic means for treating acne. Similarly, when the composition contains an effective amount of an anti-dandruff agent, a depilatory agent, an anti-aging agent or a depigmentation agent, the composition and methods of this invention provide an effective, economic means for treating the 10 symptoms of dandruff, removing hair, preventing the signs of aging and depigmenting the skin, respectively.

10

15 Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims.

15

Brief Description of the Drawings

The invention will be more fully understood and further advantages will become apparent when reference is made to the following detailed description of the invention and the accompanying drawings in which:

20

FIG 1(A) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of a formulation comprised of the 2% minoxidil-containing solution of Example 1 thereto, and the corresponding histological view associated therewith.

25

FIG 1(B) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the formulation comprised of polyoxyethylene-10 stearyl ether and 2% minoxidil of Example 2 thereto, and the corresponding histological view associated therewith.

30

FIG 1(C) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the formulation comprised of glyceryl dilaurate, cholesterol, polyoxyethylene-10-stearyl ether and 2% minoxidil of Example 3 thereto, and the corresponding histological view associated therewith.

FIG 1(D) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the formulation comprised of glyceryl dilaurate, polyoxyethylene-10-stearyl ether and 2% minoxidil solution of Example 4 thereto, and the corresponding histological view associated therewith.

35

FIG 1(E) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the formulation comprised of glyceryl dilaurate, cholesterol, polyoxyethylene-10-stearyl ether and 2% minoxidil of Example 7 thereto.

5 FIG 1(F) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the formulation comprised of an anhydrous solution containing 2% minoxidil (without nonionic lipids) of Example 6 thereto.

10 FIG 1(G) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the minoxidil-free formulation comprised of the minoxidil-free formulation containing polyoxyethylene-10 stearyl ether of Example 8, Control #1 thereto.

15 FIG 1(H) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the minoxidil-free formulation containing glyceryl dilaurate, cholesterol, polyoxyethylene-10-stearyl ether of Example 8, Control #2 thereto.

20 FIG 1(I) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the minoxidil-free formulation containing glyceryl dilaurate and polyoxyethylene-10-stearyl ether of Example 8, Control #3 thereto.

25 FIG 1(J) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of the minoxidil-free formulation containing glyceryl dilaurate of Example 8, Control #4 thereto.

20 FIG 1(K) is a representation of the dorsal view of the skin of C3H mice taken 19 days after shaving without subsequent treatment (Negative Control of Example 9), and histology corresponding therewith.

25 FIG 1(L) is a representation of the dorsal view of the skin of C3H mice taken 19 days after topical application of a Neet hair removal depilatory cream thereto (Positive Control of Example 9).

Detailed Description of the Invention

30 It is believed that one skilled in the art can, based upon the description herein, utilize the present invention to its fullest extent. The following specific embodiments are to be construed as merely illustrative, and not limitive of the remainder of the disclosure in any way whatsoever.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Also, all publications, patent applications, patents, and other references

30 The first compound of the composition of the present invention is a non-ionic lipid such as glyceryl monoesters having a fatty acid chain containing from about 3 to about 50 carbon atoms, and preferably from about 10 to about 18 carbon atoms; glyceryl diesters having a fatty acid chain containing from about 5 carbon atoms to about 25 carbon atoms,

5 and preferably from about 10 carbon atoms to about 18 carbon atoms; alkoxylated alcohols; alkoxylated alkyl phenols; alkoxylated acids; alkoxylated amides; alkoxylated sugar derivatives; alkoxylated derivatives of natural oils or waxes; polyoxyethylene polyoxypropylene block copolymers; polyoxyethylene ether fatty acids having a fatty acid chain containing from about 10 carbon atoms to about 18 carbon atoms; steroids; fatty acid esters of alcohols where the fatty acid is straight or branched chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or branched chain having 10
10 1 to 10 carbon atoms; and mixtures thereof, wherein the alkoxylated lipids are alkoxylated with ethylene oxide or propylene oxide, with ethylene oxide being preferred.

15 Examples of suitable glyceryl monoesters include, but are not limited to, glyceryl caprate, glyceryl caprylate, glyceryl cocate, glyceryl erucate, glyceryl hydroxystearate, glyceryl isostearate, glyceryl lanolate, glyceryl laurate, glyceryl linolate, glyceryl myristate, glyceryl oleate, glyceryl PABA, glyceryl palmitate, glyceryl ricinoleate, glyceryl stearate, glyceryl thiglycolate, and mixtures thereof, with glyceryl laurate and glyceryl myristate being preferred.


20 Examples of suitable glyceryl diesters include, but are not limited to, glyceryl dilaurate, glyceryl dioleate, glyceryl dimyristate, glyceryl distearate, glyceryl sesuioleate, glyceryl stearate lactate, and mixtures thereof, with glyceryl dilaurate and glyceryl dimyristate being preferred.

25 Examples of suitable polyoxyethylene fatty ethers include, but are not limited to, polyoxyethylene cetyl/stearyl ether, polyoxyethylene cholesterol ether, polyoxyethylene laurate or dilaurate, polyoxyethylene stearate or distearate, polyoxyethylene lauryl or stearyl ether, and mixtures thereof, wherein the polyoxyethylene head group ranges from about 2 to about 100 groups. Preferred polyoxyethylene fatty ethers include polyoxyethylene stearyl ether, polyoxyethylene myristyl ether, and polyoxyethylene lauryl ether having from about 3 to about 10 oxyethylene units.

30 Examples of suitable steroids include, but are not limited to, cholesterol, betasitosterol, bisabolol, and mixtures thereof.

35 Examples of suitable fatty acid esters of alcohols include isopropyl myristate, aliphati-isopropyl n-butyrate, isopropyl n-hexanoate, isopropyl n-decanoate, isopropyl palmitate, octyldodecyl myristate.

Exemplary alkoxylated alcohols useful as the toningnic lipid in the compositions of the invention have the structure shown in formula I below:



5 Formula I


wherein R_s is a branched or unbranched alkyl group having from about 6 to about 22 carbon atoms and y is between about 4 and about 100, and preferably, between about 10 and about 100. A preferred alkoxylated alcohol is the species wherein R_s is a lauryl group and y has an average value of 23, which is known by the CTFA name "laureth 23" and is available from ICI Americas, Inc. of Wilmington, Delaware under the tradename, "BRIJ 35."

10

Another exemplary alkoxylated alcohol is an ethoxylated derivative of lanolin alcohol. Lanolin alcohol is a mixture of organic alcohols obtained from the hydrolysis of lanolin. An example of an ethoxylated derivative of lanolin alcohol is laneth-10, which is the polyethylene glycol ether of lanolin alcohol with an average ethoxylation value of 10.

15

Another exemplary alkoxylated alcohol is polyoxypropylene polyoxyethylene alkyl ether, the structure of which is shown schematically in formula II below:




Formula II

20

wherein $x:q$ is about 2:2 to about 38:37. An exemplary member of this class of materials is the material known by the CTFA name "PPG-12-Buteth-16," which conforms to structure II above wherein R is a butyl group, x has an average value of 12 and y has an average value of 16. This material is available from Amerchol Corp. of Edison, New Jersey under the tradename, "UCON Fluid 50-HB-660."

Another type of non-ionic lipids include alkoxylated alkyl phenols, which generally conform to the structure:

25




30

wherein R_s is a branched or unbranched alkyl group having about 6 to about 22 carbon atoms and z is between about 7 and 120, and preferably, between about 10 and about 120. An especially preferred member of this class of materials is the species wherein R_s is a


5 nonyl group and z has an average value of about 14. This material is known by the CTFA name "nonoxynol-14" and is available under the tradename, "MAKON 14" from the Stepan Company of Northfield, Illinois.

10 Another type of non-ionic lipids include alkoxylated acids, which are esters of an acid, most usually a fatty acid, with a polyalkylene glycol. An exemplary material of this class has the CTFA name "PEG-8 laurate," and the following structure shown in formula IV.:




Formula IV

15 Another type of non-ionic lipids includes the alkoxylated amides that may conform to one or both of structures V or VI shown below:



Formula V



Formula VI

wherein n is from about 8 to about 100 and the sum of m plus b is from about 8 to about 100.


An exemplary member of this class is known by the CTFA name "PEG-6 Cocoamide," which conforms generally to structure V wherein R'CO represents the fatty acids derived from coconut oil and n has an average value of about 6.

25 Another type of non-ionic lipids includes the alkoxylated sugar derivatives. An exemplary member of this class, which is known by the CTFA name "Polysorbate 20," is a mixture of laurate esters of sorbitol and sorbitol anhydrides, consisting predominately of the monoester, condensed with about 20 moles of ethylene oxide. This material is available under the tradename "TWEEN 20" from ICI Americas of Wilmington, Delaware.

30 Another example of an alkoxylated sugar derivative useful in the compositions of the invention is the sesquiester of methyl glucose and stearic acid, contains an average of 20 moles of ethylene oxide, and is available under the tradename, "Glucamate SSE-20" from the Amerchol Corp. of Edison, New Jersey.

5 Another type of non-ionic lipids includes the alkoxylated derivatives of natural oils and waxes. Examples of this class of material include PEG-40 lanolin, PEG-40 castor oil and PEG-40 hydrogenated castor oil.

10 Another type of non-ionic lipids includes polyoxyethylene polyoxypropylene block copolymers. These materials are generally known by the CTFA name, "Poloxamer" and conform to the structure VII.:



Formula VII

15 wherein a:d:e is from about 2:16:2 to about 98:67:98. Exemplary members of this class of materials useful in the compositions of the invention are "Poloxamer 101" and "Poloxamer 182," in which a, d, and e have average values of 2, 16 and 2 and 8, 30 and 8, respectively.

20 Preferred nonionic lipids include polyoxyethylene fatty ethers, glyceryl diesters, and mixtures thereof. More preferred nonionic lipids include polyoxyethylene stearyl ether, polyoxyethylene myristyl ether, and polyoxyethylene lauryl ether, glyceryl dilaurate, glyceryl dimystate, glyceryl distearate, and mixtures thereof, whereby each ether has from about 5 to about 10 oxyethylene units.

25 In an embodiment wherein the reduction of skin irritation is a concern, it is preferable to use a nonionic lipid having a greater amount of carbon atoms on the hydrophilic head group moiety, or in the alternative, a nonionic lipid having a greater amount of carbon atoms on the hydrophobic fatty acid chain moiety. The former can be achieved by increasing the amount of carbon atoms on the head group of, for example, a polyoxyethylene-10-stearyl ether from about 10 carbon atoms to from about 15 to 20 carbon atoms. The latter can be achieved by increasing the amount of carbon atoms on the 12 carbon fatty acid tail of, for 30 example, glyceryl diesters to from about 14 carbons to about 16 carbons.

The composition of the present invention includes, based upon the total weight of the composition, from about 1 percent to about 10 percent, and preferably from about 3

35 The second compound in the composition is a vehicle solution comprised of a first vehicle component and a second vehicle component. The first vehicle component may be comprised of water, or a mixture of water and a hydrophilic compound such as soymilk. The

5 second vehicle component may be comprised of an alkanol, a polyol, or mixtures thereof. Mixtures of water and both an alkanol and a polyol are preferred, with mixtures of water, alkanols having from about 2 to about 4 carbon atoms, and polyols having from about 2 to about 10 carbon atoms being more preferred. Mixtures of water, ethanol, and propylene glycol are most preferred. For anti-aging applications it is preferable to use a mixture of 10 water along with the alkanol and/or polyol.

The vehicle solution is present in an amount, based upon the total weight of the composition, from about 74 percent to about 98 percent, preferably from about 80 percent to about 95 percent, and more preferably from about 86 percent to about 92 percent.

15 Suitable alkanols are those having from about 2 carbon atoms to about 12 carbon atoms, and preferably from about 2 carbon atoms to about 4 carbon atoms, with ethanol being the most preferred.

20 Suitable polyols are those having from about 2 carbon atoms to about 15 carbon atoms, and preferably from about 2 carbon atoms to about 10 carbon atoms and may include, but not be limited to propylene glycol, polyethylene glycol, diethylene glycol, triethylene glycol, glycerol, hexanetriol and copolymers or mixtures thereof. A preferred polyol is propylene glycol.

25 The alkanols, polyols, or mixtures thereof may be present in the vehicle solution in an amount, based upon the total weight of the vehicle solution, of from about 35 percent to about 90 percent, and preferably from about 70 percent to about 90 percent.

Water is present in the vehicle solution in an amount, based upon the total weight of the vehicle solution, of from about 5 percent to about 50 percent, and preferably from about 10 percent to about 30 percent. In a preferred embodiment wherein minoxidil is the active substance, water is present in an amount, based upon the total weight of the vehicle solution, of from about 20% to about 50%, and preferably from about 20% to about 40%.

30 In a preferred embodiment, the vehicle solution contains, based upon the total weight of the vehicle solution, water, alcohol, and a polyol in a ratio of about 1 to about 10 (water); about 3 to about 10 (alcohol); about 1 to about 10 (polyol), respectively. More preferably, the vehicle solution contains, based upon the total weight of the vehicle solution, water, ethanol, and polyethylene glycol in a ratio of about 1 to about 4 (water); about 2 to about 6 (ethanol); and about 1 to about 4 (polyethylene glycol), respectively.

In one embodiment, the non-ionic lipid and vehicle solution may be combined by initially heating the non-ionic lipid at ambient pressure to a temperature above its melting point for a period of time until the lipid is substantially melted. Typically this temperature may be from about 30°C to about 80°C, and the period of time may be from about 1 minute to

5 about 5 minutes. After the lipid is melted, the second vehicle component is added thereto at the elevated temperature, then the resulting mixture is cooled to 25°C. The first vehicle component is then added to the resulting mixture at ambient temperature and pressure.

10 In a preferred embodiment using a second vehicle component comprised of an alcohol and a polyol, only the alcohol is added to the melted lipid at the elevated temperature in order to enhance the solubility of the lipid. Then, the polyol and water are added thereto at ambient temperature and pressure conditions.

15 The non-ionic lipid and the vehicle solution of the present invention are preferably combined with a benefit agent. By "benefit agent," it is mean any active ingredient that is to be delivered into and/or onto the skin at a desired location, such as a cosmetic agent or a pharmaceutical agent. By "cosmetic agent," it is meant any ingredient that is appropriate for 20 cosmetically treating, providing nutrients to, and/or conditioning the hair and/or skin via topical application. By "pharmaceutical agent," it is mean any drug that is either hydrophobic or hydrophilic in nature and appropriate for topical use. As used herein "medicament agents" include those agents capable of promoting recovery from injury and illness.

25 Examples of suitable benefit agents include, but are not limited to, depigmentation agents; reflectants; humectants; antimicrobial (e.g., antibacterial) agents; allergy inhibitors; anti-acne agents; anti-aging agents; anti-wrinkling agents, antiseptics; analgesics; antitussives; antipruritics; local anesthetics; anti-hair loss agents; hair growth promoting agents; hair growth inhibitor agents, antihistamines; antiinfectives; inflammation inhibitors; 30 anti-emetics; anticholinergics; vasoconstrictors; vasodilators; wound healing promoters; peptides, polypeptides and proteins; deodorants and anti-perspirants; skin emollients and skin moisturizers; hair conditioners; hair softeners; hair moisturizers; tanning agents; skin lightening agents; antifungals such as antifungals for foot preparations; depilating agents; external analgesics; counterirritants; hemorrhoidals; insecticides; poison ivy products; poison oak products; burn products; anti- diaper rash agents; prickly heat agents; make-up preparations; vitamins; amino acids and their derivatives; herbal extracts; retinoids; flavoids; sensates; anti-oxidants; skin conditioners; hair lighteners; chelating agents; cell turnover enhancers; coloring agents; sunscreens and the like, and mixtures thereof. The amount of certain cleansing composition/delivery system compounds for the benefit agent purposes set forth below is in addition to the amount of the same compound that may be desired for use in the cleansing composition/delivery system thereto.

35 Examples of suitable reflectants nonexclusively include mica, alumina, calcium silicate, glycol dioleate, glycol distearate, silica, sodium magnesium fluorosilicate, and mixtures thereof.


5 Examples of suitable UV absorbers include benzophenone, bornelone, butyl paba, cinnamidopropyl trimethyl ammonium chloride, disodium distyrylbiphenyl disulfonate, paba, potassium methoxycinnamate, and mixtures thereof.

10 Commercially available humectants which are capable of providing moisturization and conditioning properties to the cleansing composition are suitable for use in the present invention. The humectant is preferably present in an amount of from about 0 percent to about 10 percent, more preferably from about 0.5 percent to about 5 percent, and most preferably from about 0.5 percent to about 3 percent, based on the overall weight of the composition. Examples of suitable humectants nonexclusively include: 1) water soluble liquid polyols selected from the group comprising glycerine, propylene glycol, hexylene glycol, butylene 15 glycol, pentylene glycol, dipropylene glycol, and mixtures thereof; 2) polyalkylene glycol of the formula VIII:



Formula VIII.

20 wherein R'' is an alkylene group having from about 2 to about 4 carbon atoms and r is an integer of from about 1 to about 10, such as PEG 4; 3) polyethylene glycol ether of methyl glucose of formula IX:



Formula IX.

25 wherein s is an integer from about 5 to about 25; 4) urea; 5) fructose; 6) glucose; 7) honey; 8) lactic acid; 9) maltose; 10) sodium glucuronate; and 11) mixtures thereof, with glycerine being the preferred humectant.

30 Suitable amino acid agents include amino acids derived from the hydrolysis of various proteins as well as the salts, esters, and acyl derivatives thereof. Examples of such amino acid agents nonexclusively include amphoteric amino acids such as alkylamido alkylamines, i.e. stearyl acetyl glutamate, capryloyl silk amino acid, capryloyl collagen amino acids; capryloyl kertain amino acids; capryloyl pea amino acids; cocodimonium 35 hydroxypropyl silk amino acids; corn gluten amino acids; cysteine; glutamic acid; glycine; alpha-hydroxyproline; alpha-hydroxyglutamate; alpha-hydroxyglutamic acid; alpha-hydroxyglutamine acid; proline, glycine, alanine, half-cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, cysteic acid, lysine, histidine, arginine, cysteine, tryptophan, citrulline; lysine; silk amino acids, wheat amino acids; and mixtures thereof

5 Suitable peptides, polypeptides, and proteins include those polymers that have a long chain, i.e. at least about 10 carbon atoms, and a high molecular weight, i.e. at least about 1000, and are formed by self-condensation of amino acids. Nonexclusive examples of such proteins include collagen, deoxyribonuclease, iodized corn protein; keratin; milk protein; protease; serum protein; silk; sweet almond protein; wheat germ protein; wheat protein; wheat protein, alpha and beta helix of keratin proteins; hair proteins, such as 10 intermediate filament proteins, high-sulfur proteins, ultrahigh-sulfur proteins, intermediate filament-associated proteins, high-tyrosine proteins, high-glycine tyrosine proteins, trichohyalin, and mixtures thereof.

15 Examples of suitable vitamins nonexclusively include vitamin B complex; including thiamine, nicotinic acid, biotin, pantothenic acid, choline, riboflavin, vitamin B6, vitamin B12, pyridoxine, inositol, carnitine; vitamins A,C,D,E,K and their derivatives such as vitamin A palmitate and pro-vitamins, e.g. (i.e. panthenol (pro vitamin B5) and panthenol triacetate) and mixtures thereof.

20 Examples of suitable antibacterial agents nonexclusively include bacitracin, erythromycin, neomycin, tetracycline, chlortetracycline, benzethonium chloride, phenol, and mixtures thereof.

Examples of suitable skin emollients and skin moisturizers nonexclusively include mineral oil, lanolin, vegetable oils, isostearyl isostearate, glyceryl laurate, methyl gluceth 10, methyl gluceth 20 chitosan, and mixtures thereof.

25 Examples of suitable hair conditioners nonexclusively include quaternized compounds such as behenamidopropyl PG-dimonium chloride, tricetylammonium chloride, dihydrogenated tallowamidoethyl hydroxyethylmonium methosulfate, and mixtures thereof as well as lipophilic compounds like cetyl alcohol, stearyl alcohol, hydrogenated polydecene, and mixtures thereof.

30 An example of a suitable hair softener nonexclusively includes silicone compounds, such as those that are either non-volatile or volatile and those that are water soluble or water insoluble. Examples of suitable silicones include organo-substituted polysiloxanes, which are either linear or cyclic polymers of monomeric silicone/oxygen monomers and which nonexclusively include cetyl dimethicone; cetyl triethylammonium dimethicone copolyol; soy protein/dimethicone copolyol acetate; silicone quaternium 13; stearalkonium dimethicone copolyol phthalate; stearamidopropyl dimethicone; and mixtures thereof.


Examples of suitable hair moisturizers nonexclusively include panthenyl ethyl ether, phytantriol, and mixtures thereof.

5 Examples of sunscreen agents nonexclusively include butyl methoxydibenzoylmethane, octyl methoxycinnamate, oxybenzone, octocrylene, octyl salicylate, phenylbenzimidazole sulfonic acid, ethyl hydroxypropyl aminobenzoate, methyl anthranilate, aminobenzoic acid, cinoxate, diethanolamine methoxycinnamate, glyceryl aminobenzoate, titanium dioxide, zinc oxide, oxybenzone, padimate o, red petrolatum, and mixtures thereof.

10 An example of a suitable tanning agent nonexclusively includes dihydroxyacetone.

Examples of skin lightening agents nonexclusively include hydroquinone, catechol and its derivatives, ascorbic acid and its derivatives, and mixtures thereof.

15 Examples of suitable insecticides (including insect repellents, anti-scabies and anti-lice treatments) nonexclusively include permethrin, pyrethrin, piperonyl butoxide, imidacloprid, N,N-diethyl toluamide, which refers to the material containing predominantly the *meta* isomer, i.e., N,N-diethyl-*m*-toluamide, which is also known as DEET; compounds of the formula X:



Formula X

25 wherein R'₅ is a branched or unbranched alkyl group having about 1 to about 6 carbon atoms, R'₆ is H, methyl or ethyl, R₇ is a branched or unbranched alkyl or alkoxy group having from about 1 to about 8 carbon atoms, and K is a -CN or a -COOR₈ group, wherein R₈ is a branched or unbranched alkyl group having from about 1 to about 6 carbon atoms; natural or synthetic pyrethroids, whereby the natural pyrethroids are contained in pyrethrum, the extract of the ground flowers of *Chrysanthemum cinerariaefolium* or *C coccineum*; and mixtures thereof. Within the structure of Formula XI. are ethyl 3-(N-

30 butylacetamido)propionate, wherein R₇ is a CH₃ group, R'₅ is an n-butyl group, R'₆ is H, K is COOR₈ and R₈ is ethyl, which is available commercially from Merck KGaA of Darmstadt, Germany under the name, "Insect Repellent 3535."

35 An example of an anti fungal topical preparation nonexclusively includes tolnaftate.

Examples of suitable depilating agents nonexclusively include calcium thioglycolate, magnesium thioglycolate, potassium thioglycolate, strontium thioglycolate, and mixtures thereof.

5 Examples of suitable external analgesics and local anesthetics nonexclusively include benzocaine, dibucaine, benzyl alcohol, camphor, capsaicin, capsicum, capsicum oleoresin, juniper tar, menthol, methyl nicotinate, methyl salicylate, phenol, resorcinol, turpentine oil, and mixtures thereof.

10 Examples of suitable antiperspirants and deodorants nonexclusively include aluminium chlorohydrates, aluminium zirconium chlorohydrates, and mixtures thereof.

Examples of suitable counterirritants nonexclusively include camphor, menthol, methyl salicylate, peppermint and clove oils, ichthammol, and mixtures thereof.

An example of a suitable inflammation inhibitor nonexclusively includes hydrocortisone.

15 Examples of suitable hemorrhoidal products nonexclusively include the anesthetics such as benzocaine, pramoxine hydrochloride, and mixtures thereof; antiseptics such as benzethonium chloride; astringents such as zinc oxide, bismuth subgallate, balsam Peru, and mixtures thereof; skin protectants such as cod liver oil, vegetable oil, and mixtures thereof.

20 Examples of suitable make-up preparations nonexclusively include components for lipstick, rouge, blush, eye liner, eyeshadow powder, mascara, face powder, and mixtures thereof.

25 One preferred type of benefit agent includes those therapeutic components that are effective in the treatment of dandruff, seborrheic dermatitis, and psoriasis as well as the symptoms associated therewith. Examples of such suitable benefit agents nonexclusively include zinc pyrithione, shale oil and derivatives thereof such as sulfonated shale oil, selenium sulfide, sulfur, salicylic acid; coal tar; povidone-iodine, imidazoles such as ketoconazole, dichlorophenyl imidazolidoxalan, which is commercially available from Janssen Pharmaceutica, N.V., under the tradename, "Elubiol", clotrimazole, itraconazole, 30 miconazole, climbazole, tioconazole, sulconazole, butoconazole, fluconazole, miconazolene nitrite and any possible stereo isomers and derivatives thereof such as anthralin; piroctone olamine (Octopirox); selenium sulfide; ciclopirox olamine; anti-psoriasis agents such as vitamin D analogs, e.g. calcipotriol, calcitriol, and tacaleitrol; vitamin A analogs such as esters of vitamin A, e.g. vitamin A palmitate, retinoids, retinols, and retinoic acid; mixtures thereof.

The amount of benefit agent to be combined with the composition of the present invention may vary depending upon, for example, the benefit agent being used, the resulting benefit desired and the sensitivity of the user to the benefit agent. Unless otherwise

expressed herein, preferably the benefit agent is present in the cleansing composition or delivery system in an amount, based upon the total weight of the composition, from about 0.001 percent to about 20 percent, and preferably from about 0.001 percent to about 10 percent, and more preferably from about 0.001 percent to about 5 percent.

As stated above, pharmaceutical agents include a broad class of chemical and therapeutic agents which are sufficiently potent such that they can be delivered into the skin or mucous membranes in sufficient quantities to produce the desired therapeutic effect. In general, this includes therapeutic agents in all of the major therapeutic areas including, but not limited to, anti-infectives, such as antibiotics and antiviral agents, analgesics and analgesic combinations, antiarthritics, antidepressants, antidiabetic agents, antihistamines, anti-inflammatory agents, antimigraine preparations, antinauseants, antineoplastics, antipruritics, antipsychotics, xanthine derivatives, cardiovascular preparations including calcium channel blockers, beta-blockers, antiarrhythmics, antihypertensives, diuretics, vasodilators including general, coronary, peripheral and cerebral; hormones, immunosuppressives, and muscle relaxants.

In particular, the pharmaceutical agent is present in sufficient amounts to enable its delivery into the skin and/or pilosebaceous units, i.e. hair follicles having sebaceous glands, to produce the desired therapeutic effect. Typically, that amount may range, based upon the total weight of the composition, from about 0.01 percent to about 20 percent, and preferably from about 2 percent to about 5 percent.

Many of the benefit agents of the present invention may be classified as one or more of the following: anti-acne agents, anti-aging agents, depigmentation agents, hair growth inducing agents, hair loss inhibiting agents, and hair growth prohibiting agents.

Preferred benefit agents include 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, which is also known as minoxidil and is described in U.S. Patent Nos. 4,139,619 and 4,596,812, the disclosures of which are incorporated by reference herein in their entireties; retinoids (e.g., retinol) and derivatives thereof; imidazoles such as ketoconazole, elubiol, econazole, itraconazole, miconazole; other anti-fungals include clotrimazole, terconazole, tioconazole, fluconazole, butoconazole, oxiconazole, and sulconazole; 5 alpha-reductase inhibitors such as finasteride; or mixtures thereof.

Most preferred benefit agents nonexclusively include sulfonated shale oil, elubiol, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, finasteride, ketoconazole, salicylic acid, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride, tricetyl ammonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin A and derivatives thereof (e.g., tretinoin), vitamin B and

5 derivatives thereof, vitamin C and derivatives thereof, vitamin D and derivatives thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, keratin, lysine, arginine, hydrolyzed wheat proteins, hydrolyzed silk proteins, octyl methoxycinnamate, oxybenzone, minoxidil, titanium dioxide, zinc dioxide, erythromycin, and mixtures thereof.

10 A preferred embodiment includes the following benefit agents: 1) a mixture of ketoconazole and minoxidil at a weight ratio of about 0.1 part to about 10 parts, and preferably from about 0.5 parts to about 5 parts ketoconazole: about 1 part to about 5 parts minoxidil; and 2) a mixture of finasteride and minoxidil at a weight ratio of about 1 part to about 10 parts, and preferably from about 0.5 parts to about 5 parts finasteride: about 1 part to about 5 parts minoxidil.

15 In one embodiment directed towards the treatment of hair loss, one preferred active substance includes minoxidil in combination with an alpha hydroxy acid, such as, for example lactic acid and/or glycolic acid, and/or a sulfonated molecule such as, for example sodium sulfate, at a minoxidil:alpha hydroxy acid:sulfonated molecule weight ratio of about 1:1:0 to about 1:10:10 or about 1:0:1 to about 1:10:10.

20 In a preferred embodiment in which the active component is minoxidil, a suitable amount of minoxidil is, based upon the total weight of composition, from greater than about 0 percent to about 20 percent, and preferably from about 1 percent to about 5 percent.

25 The vehicle solution and non-ionic lipid, when combined with the benefit agent, are present in an amount effective to enable a sufficient amount of the benefit agent into the skin. While the amount of vehicle solution and non-ionic lipid used will vary with the type and amount of benefit agent available, the intended usage of the final composition, i.e. therapeutic versus maintenance regimen, and sensitivity of the individual user to the composition, typically the weight ratio of non-ionic lipid: benefit agent may vary from about 1 to about 20 parts non-ionic lipid: to about 0.1 to about 20 parts benefit agent, and preferably from about 1 to about 5 parts non-ionic lipid: to about 0.1 to about 10 parts benefit agent.

30 The weight ratio of vehicle solution: benefit agent may vary from about 1 to about 95 parts vehicle solution: to about 0.1 to about 20 parts benefit agent, and preferably from about 50 to about 95 parts vehicle solution: to about 0.1 to about 5 parts benefit agent

35 The non-ionic lipid, the vehicle solution, and the benefit agent may be combined under ambient conditions via any conventional mixing apparatus known in the art, although it is preferable to produce a lipid-second vehicle component premixture as aforementioned. The resulting combination possesses particle sizes in the range of about 1 nm to about 500 nm, and preferably from about 1 nm to about 20 nm. In one preferred embodiment wherein the composition contains both a polyol and an alcohol at a cumulative concentration that is

less than or about equal to that of the hydrophilic component, the resulting composition is micellar in nature.

The composition of this invention can be formulated in a variety of dosage forms for topical application that include, but are not limited to, for example, lotions, creams, ointments, sprays, aerosols, skin patches, soap, mousses, tonics, gels or the like which is designed to be left on the skin and not washed shortly after application. Alternatively, the composition may be applied to the desired area in the form of, for example, a lotion, cream, gel, soap, shampoo or the like which is designed to be rinsed off within a given amount of time after application.

Another embodiment of the present invention is directed to a method for enhancing the topical application of benefit agents which comprises topically administering to a human or animal a composition as described above.

While the amount of the vehicle solution and non-ionic lipid to be applied will depend upon, for example, the type and amount of benefit agent available, the intended usage of the final composition, i.e. therapeutic versus maintenance regimen, and sensitivity of the individual user to the composition, typically the composition of the present invention should be topically applied to affected body parts at regular intervals, and preferably from about 5 to about 7 times per week. More preferably, the composition is applied more frequently during the initial stages of treatment, e.g. from about 5 to about 7 times per week until the desired effect is achieved, then less frequently when maintenance is desired, e.g. from about 3 to about 5 times per week.

In a preferred embodiment wherein the composition is incorporated into a shampoo, the shampoo is applied to wet hair, and the hair is washed in accordance with known practices. More preferably, the composition remains on the hair for greater than about 0 to about 10 minutes, and preferably from about 4 to about 7 minutes before rinsing.

An alternative preferred embodiment of the present invention is directed to a method for treating hair loss, such as hair loss resulting from alopecia, comprising topically applying to skin at a desired area for hair regrowth the above-described composition wherein the active substance is comprised of an effective amount of a hair loss treatment agent such as minoxidil or mixture thereof. As used herein, "hair loss treatment agents" shall include agents capable of growing hair and/or agents capable of preventing the loss of hair. In a preferred embodiment, the composition contains, based on the total weight of the composition, from about 0.1 percent to about 20 percent, and preferably from about 1 percent to about 5 percent hair loss treatment agent.

5 Examples of benefit agents suitable for treating hair loss include, but are not limited to potassium channel openers or peripheral vasodilators, such as minoxidil, diazoxide, and compounds such as N"-cyano-N-(tert-pentyl)-N'-3-pyridinyl-guanidine ("P-1075") as disclosed in United States Patent No.: 5,244,664, which is incorporated herein by reference; vitamins, such as vitamin E and vitamin C, and derivatives thereof such as vitamin E acetate and vitamin C palmitate; hormones, such as erythropoietin, prostaglandins, such as 10 prostaglandin E1 and prostaglandin F2-alpha; fatty acids, such as oleic acid; diluretics such as spironolactone; heat shock proteins ("HSP"), such as HSP 27 and HSP 72; calcium channel blockers, such as verapamil HCL, nifedipine, and diltiazemamiloride; immunosuppresent 15 drugs, such as cyclosporin and FK-506; 5 alpha-reductase inhibitors such as finasteride; growth factors such as, EGF, IGF and FGF; transforming growth factor beta; tumor necrosis factor; non-steroidal anti-inflammatory agents such as benoxaprofen; retinoids such as tretinoin; cytokines, such as IL-6, IL-1alpha, and IL-1beta; cell adhesion molecules such as ICAM; glucocorticoids such as betametasone; botanical extracts such as aloe, clove, ginseng, rehmannia, swertia, sweet orange, zanthoxylum, Serenoa repens (saw palmetto), 20 Hypoxis rooperi, stinging nettle, pumpkin seeds, and rye pollen; other botanical extracts including sandalwood, red beet root, chrysanthemum, rosemary, burdock root and other hair growth promoter activators which are disclosed in DE 4330597 which is incorporated by reference in its entirety herein; homeopathic agents such as Kalium Phosphoricum D2, Azadirachta indica D2, and Joborandi D1; genes for cytokines, growth factors, and male- 25 pattern baldness; antifungals such as ketoconazole, and elubiol; antibiotics such as streptomycin; proteins inhibitors such as cycloheximide; acetazolamide; benoxaprofen; cortsone; diltiazem; hexachlorobenzene; hydantoin; nifedipine; penicillamine; phenothaiazines; pinacidil; psoralens, verapamil; zidovudine; alpha-glucosylated rutin having at least one of the following rutins: quercetin, isoquercitrin, hesperidin, naringin, and 30 methylhesperidin, and flavonoids and transglycosidated derivatives thereof which are all disclosed in JP 7002677, which is incorporated by reference in its entirety herein; and mixtures thereof.

Preferred hair loss treatment agents include 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, N"-cyano-N-(tert-pentyl)-N'-3-pyridinyl-guanidine, finasteride, a retinoid and derivatives thereof, ketoconazole, or mixtures thereof.

Another embodiment of the present invention is directed to a method for removing hair comprising topically applying to skin at a desired area for removing hair the above-described composition, e.g. the combination of non-ionic lipid and vehicle solution, containing an effective amount of a depilatory agent, such as the thioglycolades, e.g.

5 calcium thioglycolate, magnesium thioglycolate, potassium thioglycolate, strontium thioglycolate, and mixtures thereof. In a preferred embodiment, the composition contains, based upon the total weight of the composition, from about 0.001 percent to about 20 percent, and preferably from about 0.01 percent to about 5 percent hair depilatory agent.

10 Another embodiment of the present invention is directed to a method for inhibiting hair growth comprising topically applying to skin at a desired area for inhibiting hair growth the above-described composition, e.g. the combination of non-ionic lipid and vehicle solution, containing an effective amount of a hair growth inhibiting agent. In a preferred embodiment, the composition contains, based upon the total weight of the composition, from about 0.001 percent to about 20 percent, and preferably from about 0.01 percent to about 5 percent hair growth inhibiting agent.

15 Examples of benefit agents suitable for use in inhibiting hair growth include: serine proteases such as trypsin, vitamins such as alpha-tocopherol (vitamin E) and derivatives thereof such as tocopherol acetate and tocopherol palmitate; antineoplastic agents, such as doxorubicin, cyclophosphamide, chloromethine, methotrexate, fluorouracil, vincristine, daunorubicin, bleomycin and hydroxycarbamide; anticoagulants, such as heparin, heparinoids, coumaerins, detran and indandiones; antithyroid drugs, such as iodine, thiouracils and carbimazole; lithium and lithium carbonate; interferons, such as interferon alpha, interferon alpha-2a and interferon alpha-2b; retinoids, such as retinol (vitamin A), isotretinoin; glucocorticoids such as betamethasone, dexamethasone; Antihyperlipidaemic drugs, such as triparanol and clofibrate; thallium; mercury; albendazole; allopurinol; amiodarone; amphetamines; androgens; bromocriptine; butyrophrenones; carbamazepine; cholestyramine; cimetidine; clofibrate; danazol; desipramine; dixyrazine; ethambutol; etionamide; fluoxetine; gentamicin, gold salts; hydantoins; ibuprofen; impramine; immunoglobulins; indandiones; indomethacin; intraconazole; levodopa; maprotiline; methysergide; metoprolol; metyrapone; nadolol; nicotinic acid; potassium thiocyanate; propranolol; pyridostimine; salicylates; sulfasalazine; terfenadine; thiamphenicol; thiouracils; trimethadione; troparanol; valproic acid; and mixtures thereof. Preferred hair growth inhibitory agents include serine proteases, retinol, isotretinoin, betamethasone, alpha-tocopherol and derivatives thereof, or mixtures thereof.

30 35 Another preferred embodiment of the present invention is directed to a method for reducing acne and/or reducing the signs of aging, i.e. wrinkles, fine lines, etc. Other manifestations of photodamage, comprising topically applying to skin at a desired area the above-described composition, e.g. the combination of non-ionic lipid and vehicle solution, containing an anti-acne agent or an anti-aging agent, respectively.

5 Examples of suitable anti-aging agents include, but are not limited to inorganic sunscreens such as titanium dioxide and zinc oxide; organic sunscreens such as octyl-methyl cinnamates and derivatives thereof; retinoids; vitamins such as vitamin E, vitamin A, vitamin C, vitamin B, and derivatives thereof such as vitamin E acetate, vitamin C palmitate, and the like; antioxidants including alpha hydroxy acid such as glycolic acid, citric acid, lactic acid, malic acid, mandelic acid, ascorbic acid, alpha-hydroxybutyric acid, alpha-hydroxyisobutyric acid, alpha-hydroxyisocaproic acid, atrrolactic acid, alpha-hydroxyisovaleric acid, ethyl pyruvate, galacturonic acid, glucopehtonic acid, glucopheptono 1,4-lactone, gluconic acid, gluconolactone, glucuronic acid, glucuronolactone, glycolic acid, isopropyl pyruvate, methyl pyruvate, mucic acid, pyruvia acid, saccharic acid, saccaric acid 1,4-lactone, tartaric acid, and tartronic acid; beta hydroxy acids such as beta-hydroxybutyric acid, beta-phenyl-lactic acid, beta-phenylpyruvic acid; botanical extracts such as green tea, soy, milk thistle, algae, aloe, angelica, bitter orange, coffee, goldthread, grapefruit, hoellen, honeysuckle, Job's tears, lithospermum, mulberry, peony, pueraria, rice, safflower, and mixtures thereof. Preferred anti-aging agents include retinoids, anti-oxidants, alpha-hydroxy acids and beta-hydroxy acid with retinol and tretinoin being most preferred.

10 Examples of suitable anti-acne agents include, but are not limited to topical retinoids (tretinoin, Isotretinoin, Motretinide, Adapalene, Tazarotene, Azelaic acid, retinol); salicylic acid; benzoyl peroxide; antibiotics such as tetracycline and isomers thereof, erythromycin, and the anti-inflammatory agents such as ibuprofen, naproxen, hetprofen; botanical extracts such as alnus, arnica, artemisia capillaris, asiasarum root, birch, calendula, chamomile, cnidium, comfrey, fennel, galla rhois, hawthorn, houttuynia, hypericum, jujube, kiwi, licorice, magnolia, olive, peppermint, philodendron, salvia, sasa albo-marginata; imidazoles such as ketoconazole and elubiol, and those described in Gollnick, H et al. 196(1) *Dermatology Sebaceous Glands, Acne and Related Disorders*, 119-157 (1998), which is incorporated by reference herein, and mixtures thereof. Preferred anti-acne agents include retinol, elubiol, antibiotics, and salicylic acid, with retinol and tretinoin being most preferred.

15 Suitable amounts of anti-aging agents include, based upon the total weight of the composition, from about 0.01 percent to about 10 percent, and preferably from about .04 percent to about 5 percent. Suitable amount of anti-acne agents include based upon the total weight of the composition, from about 0.01 percent to about 10 percent, and preferably from about .04 percent to about 5 percent.

20 Another preferred embodiment of the present invention is directed to a method for depigmenting the skin comprising topically applying to skin at a desired area the above-

5 described composition, e.g., the combination of non-ionic lipid and vehicle solution, containing a depigmentation agent. Suitable amounts of depigmentation agents include, based upon the total weight of the composition, from about 0.01 percent to about 10 percent, and preferably from about .04 percent to about 5 percent.

10 Examples of suitable depigmentation agents include, but are not limited to retinoids such as retinol; Kojic acid and its derivatives such as, for example, kojic dipalmitate; hydroquinone and its derivatives such as arbutin; tranexamic acid; vitamins such as niacin, vitamin C and its derivatives; azelaic acid; placertia; licorice; extracts such as chamomile and green tea, and mixtures thereof.

15 Another preferred embodiment of the present invention is directed to a method for treating the diseases of dandruff, seborrheic dermatitis, and psoriasis and/or the symptoms associated therewith comprising topically applying to skin at a desired area the above-described composition, e.g., the combination of non-ionic lipid and vehicle solution, containing an effective amount of an active agent selected from the group consisting of an anti-dandruff agent, an anti-seborrheic dermatitis agent, an anti-psoriasis agent, and mixtures thereof. Suitable amounts of an anti-dandruff agent, an anti-seborrheic dermatitis agent, and an anti-psoriasis agent include, based upon the total weight of the composition, from about 0.001 percent to about 10 percent, and preferably from about 0.01 percent to about 5 percent.

20 Examples of suitable anti-dandruff agents, anti-seborrheic dermatitis agents, and anti-psoriasis agents nonexclusively include zinc pyrithione, selenium sulfide, sulfur; sulfonated shale oil; salicylic acid; coal tar; povidone-iodine, imidazoles such as ketoconazole, dichlorophenyl imidazolodioxalan, clotrimazole, itraconazole, miconazole, climbazole, tioconazole, sulconazole, butoconazole, fluconazole, miconazolenitrite and any possible stereo isomers and derivatives thereof such as anthralin; piroctone olamine (Octopirox); selenium sulfide; ciclopirox olamine; anti-psoriasis agents; vitamin A analogs; corticosteroids and mixtures thereof, with elubiol, ketoconazole, coal tar, salicylic acid, zinc pyrithione, selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride and mixtures thereof being preferred.

25 In a preferred embodiment, especially with respect to hair growth, the composition of the present invention is substantially free from hydroxypropyl methyl cellulose or other film formers known in the art. By 'substantially free' it is meant no more than 0.05% of cellulose or derivatives thereof are present.

30 With respect to hair growth, we have unexpectedly found that the combination of the non-ionic lipid and the vehicle solution, especially in the absence of a higher molecular

5 weight film former, induces hair growth in about half of the time it took for prior art vehicle solutions containing such film formers to do the same. Moreover, we have particularly found that when minoxidil is the selected pharmacologically active substance, hair growth can be stimulated faster than by application of conventional vehicles such as that commercially available from Upjohn under the tradename ROGAINE™ i.e. minoxidil in a 20:60:20 v/v% polyethylene glycol/ethanol/water transport vehicle.

10 The invention illustratively disclosed herein suitably maybe practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof. Other compositions of the invention can be prepared in an analogous manner by a person of ordinary skill in the art.

15 **Example 1: Preparation of a Propylene Glycol, Ethanol and Water Formulation Containing 2% Minoxidil, with and without an alpha-hydroxy acid and sodium sulfate**

20 0.4g of minoxidil, U.S.P./N.F., available from Spectrum Quality Products Products, Inc., Gardena, CA was added with stirring into a beaker containing 4 ml of propylene glycol, 12 ml of ethanol, and 4 ml water under ambient conditions to produce a formulation containing 2% (wt/v) minoxidil. This formulation is identical to that which is commercially available from the Upjohn Company, Kalamazoo, MI under the tradename, " ROGAINE™".

25 To obtain a formulation containing an alpha-hydroxy acid (used in Example 12), 360 μ l of DL-lactic acid was then added under ambient conditions to the above ROGAINE-type formulation.

30 To obtain a formulation with both an alpha-hydroxy acid and sodium sulfate (used in Example 12), 0.626g of sodium sulfate was added under ambient conditions to the above hydroxy acid-containing formulation.

35 **Example 2: Preparation of Polyoxyethylene-10 stearyl ether Formulation Containing 2% Minoxidil**

40 After melting 0.5g of polyoxyethylene-10-stearyl ether available from ICI Surfactants, a solution of 0.25g of DL-lactic acid in 10 ml of water was added to the minoxidil containing formulation of Example 1 was added thereto with stirring until the resulting mixture was at ambient temperature in order to produce a formulation containing 2% (wt/v) minoxidil with 5% non-ionic lipids.

5 Example 3: Preparation of Three Nonionic Lipid Formulation Containing 2% Minoxidil

10 0.225g of glyceryl dilaurate available from Van Dyk & Company, Inc., Belleville, NJ under the tradename, "Emulsynt GDL," 0.075g of cholesterol available from Croda, Inc., New York, NY under the tradename, "Cholesterol NF", and 0.2g of the polyoxyethylene-10-sterol ether of Example 2 were mixed in a beaker at 50°C until the components were homogeneously melted to yield a 45:15:40 weight percent nonionic lipid mixture.

15 10 ml of the minoxidil-containing formulation of Example 1 were added to 0.5 g of the resulting non-ionic lipid mixture with stirring until the resultant mixture was at ambient temperature in order to yield a formulation containing 2% minoxidil with 5% non-ionic lipids.

15 Example 4: Preparation of Two Nonionic Lipid Formulation Containing 2% Minoxidil

20 0.25g of the glyceryl dilaurate of Example 3 and 0.25g of the polyoxyethylene-10-sterol ether of Example 3 were mixed in a beaker at 50°C until the components were homogeneously melted to yield a 50:50 weight percent nonionic lipid mixture. 10 ml of the formulation of Example 1 was added thereto with stirring until the resulting mixture was at ambient temperature in order to yield a formulation containing 2% minoxidil with 5% non-ionic lipids.

25 Example 5: Preparation of Glyceryl Dilaurate Formulation Containing 2% Minoxidil

30 After melting 0.5g of the glyceryl dilaurate of Example 2 with stirring in a beaker at 50°C, 10 ml of the Formulation of Example 1 were then added with thereto with stirring until the resulting formulation was at ambient temperature in order to yield a formulation containing 2% minoxidil with 5% non-ionic lipids.

Example 6: Preparation of Anhydrous, Non-Ionic Lipid Composition With Minoxidil

35 0.4g of the minoxidil of Example 1 were added with stirring to a beaker containing a mixture of 2 ml of propylene carbonate available from Arco, Newtown Square, PA under the tradename, "Arconate HP", 6 ml of ethanol, 1 ml of polyethylene glycol available from Dow Chemical Midland, MI, and 1 ml glycerin available from Hercules Chemical Company, Cincinnati, OH under the tradename, "Glycerin 916" under ambient conditions to produce a solution containing 2% minoxidil. 0.5g of the nonionic lipid mixture of Example 3 was then added to 10 ml of the resulting solution under ambient conditions to yield a formulation containing 2% non-ionic lipids.

5

Example 7: Preparation of a Anhydrous, Non-Ionic Lipid-Free Composition With 2% Minoxidil

10 0.4 g of the minoxidil of Example 1 were added with stirring under ambient conditions into a beaker containing a mixture of 4 ml of propylene carbonate, 12 ml of ethanol, 2 ml of propylene glycol, and 2 ml of glycerin, all of Example 6, in order to yield a non-ionic lipid-free composition containing 2 % of minoxidil.

15 **Example 8: Preparation of Minoxidil-Free Formulations**

20 Examples 1 through 5 were repeated but with the omission of the minoxidil component. The resulting formulations were identified as follows: Control 1 (POE) was the minoxidil-free formulation of example 2; Control 2 (GDL/CH/POE) was the minoxidil-free formulation of example 3; Control 3 (POE/GDL) was the minoxidil-free formulation of example 4; and Control 4 (GDL) was the minoxidil-free formulation of example 5.

25 **Example 9: Comparative Testing: Stimulation of Hair Growth in C3H Mouse Model**

30 100 μ l of the 2% minoxidil-containing compositions produced in Examples 1 through 4 and 6 through 8, respectively, were applied via pipette to approximately a 1.5 cm^2 section of dorsal skin surface of 3-5 C3H mice available from Charles River Breeding Laboratories, Kingston, NY once per day, 5 days per week for 19 days.

35 Prior to application of the above-described, respective formulations, the mice were screened for telogen (resting phase in hair growth cycle) skin on day 1 by gently blowing on their fur. The appearance of pink skin evidenced the presence of the telogen phase. After the mice were sedated with an i.p. injection of 100 μ l ketamine/xylazine solution, their hair was gently clipped with an electric clipper on their respective dorsal sides.

40 For positive control purposes, 2 similar C3H mice were shaved then depilated at the shaved dorsal section with a hair removal treatment available from Reckitt & Colman Inc, Wayne NJ under the tradename, "Neet." For negative control purposes, 2 similar C3H mice were left untreated after the shaving.

45 The mice were observed for hair growth stimulation/inhibition during the dosing period which was concluded on day 19, by monitoring due to the appearance of hair growth in the dorsal section of the mice treated with the composition of Example 2. The amount of hair growth is further evidenced in the representations of the dorsal sections illustrated in FIG. 1(A) through FIG. 1(L).

5 As shown in FIG. 1(B), the mice treated with the composition of Example 2 possessed a greater amount of hair growth in comparison to the mice treated with the ROGAINE™ treatment (see FIG. 1(A)), or the mice in the control groups (see FIGS. 1(G) – 1(L)).

10 As further evidenced in the histological representations of FIG. 1(A) through FIG. 1(D) and FIG. 1(K), it is evident that the mice treated with the enhanced vehicles from Examples 2-4 demonstrated long, anagen follicles, i.e. follicles in the growth state of the hair growth cycle, whereas the mice treated with the Rogaine formulation demonstrated follicles only in the telogen state. The untreated mice in FIG 1(K) similarly demonstrated follicles in only the telogen state. This indicated that, from a follicular perspective, the formulations produced in Examples 2-4 were superior in enhancing hair growth in contrast to the Rogaine formulations, which did not appear to stimulate hair growth at all.

15

20 This Example showed that the composition of the present invention, which contained a vehicle solution combined with a non-ionic lipid, stimulated more hair growth at a considerable faster rate in comparison to amount and rate of hair growth stimulated by the ROGAINE treatment.

25 Example 10: Preparation of a Propylene Glycol, Ethanol and Water Formulation Containing 5% Minoxidil, both with and without sodium sulfate

30 0.5g of the minoxidil of Example 1 were mixed with stirring into a beaker containing a mixture of 2 ml of propylene glycol, 6 ml of ethanol, and 2 ml water under ambient conditions to produce a formulation containing 5% minoxidil. This formulation is identical to that which is commercially available from the Upjohn Company, Kalamazoo, MI under the tradename, " ROGAINE 5%™"

35 For sodium sulfate-containing formulations (as used in Example 12), 0.313g of sodium sulfate was then added thereto.

35 Example 11: Preparation of a Novel Polyoxyethylene-10 stearyl ether, Alpha-hydroxy acid formulation with 5% minoxidil, both with and without 1.4% sodium sulfate

After melting 0.5g of the polyoxyethylene-10-sterol ether of Example 2 in a beaker at 50°C., 10 ml of the minoxidil-containing formulation of Example 1 and 260µl of DL-lactic acid were then added thereto with mixing until the resulting mixture reached ambient temperature. The resulting mixture contained 2% minoxidil with 5% non-ionic lipids and a

5 alpha-hydroxy acid. A few drops of 0.1M hydrochloric acid was then added thereto in order to adjust the pH of the resulting composition to about 4.6.

In sodium sulfate-containing formulations, 0.26g of sodium sulfate was added to the above resulting mixture before the addition of the pH-adjusting acid thereto.

10 **Example 12: Comparative Testing: Stimulation of Hair Growth in a More Resistant C57 Mouse Model**

15 100 μ l of the formulations of Example 1, 10, and 11 were applied via pipette to about a 4 cm² section of dorsal skin surface of 3-5 C57Bl/6 female, 7 week old mice available from Charles River Breeding Laboratories, Kingston, NY, respectively, once a day, 5 days per week for 25 days.

20 For positive control purposes, 5 similar C57Bl/6 mice were shaved in the same manner then depilated at the same dorsal section with the NEET hair removal treatment of Example 8. For negative control purposes, 5 similar C57Bl/6 mice were left untreated after the shaving.

25 Prior to application of the above-described, respective formulations, the mice were screened for telogen (resting phase in hair growth cycle) skin on day 1 by gently blowing on their fur. The appearance of pink skin evidenced the presence of the telogen phase. After the mice were sedated with an i.p. injection of 100 μ l ketamine/xylazine solution, their hair was gently clipped with an electric clipper on their respective dorsal sides.

30 The mice were observed for hair growth stimulation/inhibition during the dosing period. Every two days during the dosing period the status of the hair and the skin were classified and recorded as "full coat," "spotty hair," "black skin" (little or no hair) and "no hair." These number of days in each hair growth status were averaged in each dosing group and the standard deviation was determined within each dosing group. The results of this Example are shown in Table 1.

Table 1.

Formulation	Black Skin	Spotty Hair	Full Coat
Rogaine 2% {Example 1}	18 \pm 2*	22.0 \pm 0.0	>26
Rogaine 2% + Lactic acid {Example 1}	16.4 \pm 5.2	>22	>26
Rogaine 2% + Lactic acid + sodium sulfate {Example 1}	14.0 \pm 3.7	>16	>23
Rogaine 5% {Example 10}	10.5 \pm 3.8	12.0 \pm 4.0	15.5 \pm 3.0

Rogaine 5% + sodium sulfate (Example 10)	10.0±2.3	12.5±2.5	18.8±5.4
Untreated (Example 12)	>26	>26	>26
2% Minoxidil + lipid + lactic acid (Example 11)	8.0±1.5	11.5±1.9	13.5±1.9
2% Minoxidil + lipid + lactic acid + sodium sulfate (Example 11)	7.6±0.5	9.2±1.8	13.2±1.8
Neet depilatory (Example 12)	9.3±1.2	12.0±0.0	15.3±2.3

* Expressed in terms of number of days to express condition.

10 It was observed that the hair and skin of the untreated animals remained in the telogen state for the duration of the dosing period (negative control), while the hair and skin of the depilatory-treated mice started to exhibit melanogenesis after 10-25 days of dosing (positive control).

15 As shown in Table 1, the formulations that induced the most rapid onset of hair growth were those produced in Example 11, i.e. the combination of 2% minoxidil, polyoxyethylene-10-sterol ether, lactic acid, and optional sodium sulfate, with the formulation containing the sodium sulfate being the most preferred.

20 This Example showed that the formulations of Example 11, which contained only 2% minoxidil in the delivery system of the present invention, outperformed the 5%-minoxidil-containing formulation of Example 10 with respect to speed and quantity of hair growth stimulation due to the addition of the unique delivery system of the present invention that was added thereto.

25 This Example further showed that the addition of sodium sulfate to the formulations of the present invention also improved the speed and amount of hair growth.

This Example further showed that the addition of an alpha hydroxy acid ('AHA') to the 2% minoxidil-containing formulations of the present invention (Example 11) also resulted in a faster onset of thicker hair growth relative to that achieved by the 2% -minoxidil formulation in the ROGAINE vehicle (Examples 1), regardless if the latter optionally contained lactic acid and sodium sulfate.

30 Example 10: Preparation of Lipid Formulation Containing Minoxidil and Retinoinic Acid, both with and without Sodium Sulfate

5 0.4g of the minoxidil of Example 1 and 0.4g ketoconazole available from Janssen Pharmaceutica N.V., Beerse, Belgium, were added with stirring at ambient temperature and pressure into a beaker containing 4 ml of propylene glycol, 12 ml of ethanol, and 4 ml water to produce a 2% minoxidil/ketoconazole-containing solution.

10 0.5g of the polyoxyethylene-10-steral ether of Example 2 was melted in a beaker at 50°C and added into 10 ml of the 2% minoxidil/ketoconazole-containing solution with stirring until the resulting mixture reached ambient temperature in order to produce a composition containing 2% minoxidil, 2% ketoconazole, and 5% non-ionic lipids.

15 These steps were repeated but with the addition of 0.28g sodium sulfate into the mixture of water, ethanol, and propylene glycol in order to result in a composition containing 2% minoxidil, 2% ketoconazole, 5% non-ionic lipids, and 1.4% sodium sulfate.

Example 14: Preparation of Ketoconazole-Lipid Formulation

20 0.5g of the polyoxyethylene-10-steral ether of Example 2 were melted in a beaker at 50°C.

0.4g of the ketoconazole of Example 13 were added with stirring into a beaker containing a mixture of 4ml of propylene glycol, 12 ml of ethanol, and 4 ml water at ambient temperature and pressure to yield a ketoconazole-containing vehicle solution.

25 10 ml of the ketoconazole-containing vehicle solution were added into the melted ether at 50°C with stirring until the resulting mixture reached to room temperature in order to yield a composition containing 2% ketoconazole with 5% non-ionic lipids.

Example 15: Preparation of Minoxidil and Finasteride Lipid Formulation

30 0.5g of the polyoxyethylene-10-steral ether of Example 2 was melted in a beaker at 50°C.

35 0.4g of the minoxidil of Example 1 and 0.4g of finasteride available from Sigma Chemical Company, St. Louis, MO were added with stirring at ambient temperature into a beaker containing a mixture of 4ml of propylene glycol, 12 ml of ethanol, and 4 ml water to produce a vehicle solution containing finasteride and 2% minoxidil.

10 ml of the vehicle solution were then added with stirring into the melted non-ionic lipid melt at 50°C and then cooled to room temperature to yield a composition containing 2% minoxidil and 2% finasteride with 5% non-ionic lipids.

40 **Example 16: Preparation of Minoxidil-free, Finasteride -Lipid Formulation**

5

0.5g of the polyoxyethylene-10-steral ether of Example 2 was melted in a beaker at 50°C.

0.4g of the finasteride of Example 15 were added with stirring at ambient temperature into a beaker containing mixture of 4ml of propylene glycol, 12 ml of ethanol, and 4 ml water to produce a finasteride-containing vehicle solution.

10

10 ml of the vehicle solution was then added with stirring into the melted non-ionic lipid melt at 50°C and then cooled to room temperature to yield a minoxidil-free composition containing 2% finasteride with 5% non-ionic lipids.

15

Example 17: Preparation of Minoxidil-lipid formulation with Hydroxypropyl methyl cellulose

20

0.5g of polyoxyethylene-10-stearyl ether of Example 2 were melted in a beaker at 50°C. 10 ml of the minoxidil-containing formulation of Example 1 was added thereto with stirring at constant temperature. 0.05g of a hydroxypropylmethylcellulose film former available from Hercules, Inc, Wilmington, DE under the tradename, "Klucel HF" was then added thereto with stirring at constant temperature to produce a composition containing 2% minoxidil with 5% non-ionic lipids and 0.5% hydroxypropylmethylcellulose.

25

Example 18: Comparative Testing: Stimulation of Hair Growth

30

100 µl of the 2% minoxidil-containing compositions in Examples 1, 2, 10, 12-16 were independently applied via pipette to the entire dorsal skin surface of 3-5 C57Bl/6 female, 7 week old mice available from Charles River Breeding Laboratories, Kingston, NY, respectively, once per day, 5 days per week for 25 days.

35

For positive control purposes, 5 similar C57 mice were shaved in the same manner then depilated at the same dorsal section with the Neet hair removal treatment of Example 8. For negative control purposes, 5 similar C57 mice were left untreated after the shaving.

35

The animals were observed for hair growth stimulation/inhibition during the dosing period in accordance with the procedure set forth in Example 12. The results of our observations are set forth below in Table 2:

Table 2

<u>Formulation</u>	<u>Black Skin</u>	<u>Spotty Hair</u>	<u>Full Coat</u>
ROGAINE 2% (Example 1)	25.6±0.5*	>26	>26

ROGAINE 5% (Example 10)	11.5±1.0	17.0±4.8	23.0±2.4
Untreated	>26	>26	>26
ROGAINE 2% in cellulose (Example 16)	21.2±3.0	24.0±1.9	25.8±0.4
2% Minoxidil in lipid (Example 2)	9.2±1.8	12.8±1.1	16.0±1.4
2% Minoxidil in lipid with 2% Ketoconazole+ 1.4% Sodium Sulfate (Example 13)	9.6±2.2	12.8±1.8	16.4±2.6
2% Minoxidil in lipid with 2% Ketoconazole (Example 13)	9.6±1.7	12.4±2.6	16.0±3.2
MINOXIDIL-FREE, 2% Ketoconazole- lipid (Example 14)	24.0±2.8	>26	>26
2% Minoxidil in lipid with 2% Finasteride (Ex. 15)	9.2±1.8	11.0±1.1	12.5±1.8
MINOXIDIL-FREE, 2% Finasteride in lipid (Ex. 16)	14.0±3.7	18.0±3.2	25.0±0.0
Neet (Example 12-positive control)	12.0±2.0	14.7±1.2	18.7±1.2

5

* Expressed in terms of number of days to express condition.

10

As shown in Table 2, the formulations that contained the minoxidil in the novel non-ionic lipid formulation demonstrated the most rapid onset of hair growth and performed substantially better in stimulating hair growth than the ROGAINE formulations containing as much as 5% minoxidil.

We further found that the formulations containing the minoxidil and non-ionic lipid combination were superior in stimulating hair growth relative to the 2% ROGAINE formulation with cellulose of Example 16.

15

The foregoing results demonstrate that the novel non-ionic lipid formulations of the present invention are superior to the known minoxidil Rogaine formulations that contain greater than two times the amount of minoxidil as well as those minoxidil-lipid formulations containing cellulose film formers.

5 Example 19: Preparation of 2% Minoxidil Formulation containing Two Nonionic Lipids

10 0.25g of the polyoxyethylene-10-stearyl ether of Example 2 and 0.25g of
polyoxyethylene-9-lauryl ether available from Heterene, Inc., Paterson, NJ under the
tradename, "Laureth-9" were melted in a beaker at 50°C. 10 ml of the minoxidil-containing
formulation of Example 1 were added into the non-ionic lipid mixture at 50°C with stirring
until the resultant composition was at ambient temperature in order to yield a composition
containing 2% minoxidil with 5% non-ionic lipids.

15 Example 20: Delivery of Minoxidil into the Pilosebaceous Units: Determined by a Hamster
Ear Model

20 Because the hamster ear pilosebaceous units are shown to have anatomical and
physiological similarities to those of human sebaceous glands, Plewig, G. et al., "Hamster
ear model for sebaceous glands," 68: J. Invest Dermatol. 171-176 (1977) and Matias, J. R.
et al., "The hamster ear sebaceous glands. I. Examination of the regional variation by
stripping skin planarimetry." 81: J. Invest. Dermatol. 43-46 (1983), hamsters are known for
providing an effective model for estimating the extent and rate of deposition of active agents
into pilosebaceous units.

25 A trace amount of radioactive (3H) minoxidil, purchased from American
Radiolabeled Chemicals, Inc, St. Louis MO, was added to each formulation from Examples
1, 2, and 19, respectively, to produce radiolabeled formulations.

30 25 μ l of cold (without radioactivity) formulation from each respective example was
applied twice a day for one day to the ventral ear of 3 male, 10 week old, golden Syrian
hamsters obtained from Charles Rivers Breeding Laboratories, Kingston, NY i.e., six ears
per formulation. These mice were housed in separate cages under a 14 hours light and 10
hours dark cycle for two weeks before use in order to maximize androgen-dependent
sebaceous gland activity and thus control their size.

35 At 15 hours after the second application of each respective formulation and after
anesthetizing the mice, 25 μ L of the radiolabeled minoxidil formulation was similarly applied
to each ear. After 4 hours, the ears were processed according to Niemicc, S.M. et. al.,
"Influence of nonionic liposomal composition on topical delivery of peptide drugs into
pilosebaceous units: An in-vivo study using the hamster ear model" 12: Pharm. Research,
1184-1188 (1995), which is incorporated by reference herein. The results of this Example
40 are shown below in Table 3:

Table 3: Distribution of Minoxidil

Ear Strata (% radiolabelled formulation (μ g) in strata)	2% Minoxidil in Rogaine solution (Example 1)	2% Minoxidil in one nonionic lipid (Example 2)	2% Minoxidil in two nonionic lipids (Example 19)
Sebaceous Glands	0.04 \pm 0.01 (0.18 \pm 0.04)	0.12 \pm 0.02 (0.57 \pm 0.08)	0.13 \pm 0.05 (0.60 \pm 0.19)
Ventral Dermis	0.0 \pm 0.0	0.02 \pm 0.0	0.02 \pm 0.0
Cartilage	0.02 \pm 0.01	0.05 \pm 0.01	0.05 \pm 0.02
Dorsal Ear	0.01 \pm 0.0	0.04 \pm 0.01	0.04 \pm 0.01

10 It is evident from Table 3 that the formulations containing the novel delivery systems of the present invention having either one or two non-ionic lipids delivered over three times the amount of minoxidil into the sebaceous glands relative to the amount delivered by the formulations containing the known Rogaine vehicle solution.

15 This Example shows that the non-ionic lipid-containing vehicles of the present invention are more effective in delivering the active agents into the sebaceous glands and hair follicles than vehicles known in the art.

20 **Example 21: Preparation of Hair Growth Formulations**

After melting the lipids set forth below in a beaker at 50°C, the remaining ingredients, except for the active agents, are added with stirring thereto at constant temperature. After the mixture is homogeneous, the hair growth agents are added thereto with stirring at constant temperature. When these formulations are topically applied to the scalp, the rate of hair growth is improved.

Table 4

Components	Concentration (weight %)			
	Ex 1	Ex 2	Ex 3	Ranges Ex 4
Minoxidil	2	2	2	0-10
Ketoconazole	0	2	2	0-5
Finasteride	0	0	0	0-5
1,3-butyleneglycol	12.5	20	20	5-20
Propylene Glycol	12.5	20	20	1-40
Glyceryl Distearate*	2	0	0	0.0-5
Cholesterol	0	0	0.5	0-1
Glyceryl Dilaurate	0	0	1	0-5
Polyoxyethylene-9-lauryl ether (Laureth-9)	2	0	1	0-5

Polyoxyethylene-10-staryl ether (BRIG 76)	1	5	2.5	0-5
Fragrance	0.25	0.25	0.25	0-0.5
Polyoxypropylene-polyoxyethylene block polymers (Pluronic F-127)**	0	5	0	1-20
Polyacrylamine, Laueth-7, and C13-14 Isoparaffin (Sepigel 305)***	0	0	3	0-5
Water	q.s. to 100%	q.s. to 100%	q.s. to 100%	q.s. to 100%

*available from Armak Company, McCook, IL, under the tradename, "Kessco GDS 386F."

**available from BASF Wyandotte Corp., Parsippany, NJ, under the tradename "Pluronic F-127"

***available from Seppic Inc., Fairfield, NJ, under the tradename, "Sepigel-305"

10

Example 22: Preparation of Anti-aging agent-Lipid Formulations

The below formulations are prepared in accordance with the procedure set forth in Example 21. When these formulations are applied to the skin, the symptoms of aging are reduced.

Table 5

Components	Concentration (weight %)			Ranges Ex 4
	Ex 1	Ex 2	Ex 3	
Retinol*	0.15	0.15	0.15	0-2
Glycolic acid**	0	3	0	0-10
Vitamin E***	0	0	1	0-5
Ethanol	60	40	20	20-80
1,3-butylene glycol	12.5	20	20	5-20
Propylene Glycol	12.5	20	20	1-40
Glyceryl Distearate	2	0	0	0.0-5
Cholesterol	0	0	0.5	0-1
Glyceryl Dilaurate	0	0	1	0-5
Laureth-9	2	0	1	0-5
Polyoxyethylene-10-staryl ether (Brig 76)	1	5	2.5	0-5
Fragrance	0.25	0.25	0.25	0-0.5
Polyacrylamine, Laueth-7, and C13-14 Isoparaffin (Sepigel 305)	0	0	3	0-5
Polyoxypropylene block polymers (Pluronic F-127)	(1)	5	0	1-20
water	q.s. to 100%	q.s. to 100%	q.s. to 100%	q.s. to 100%

15

* available from BASF Corp., Parsippany NJ under the tradename, "Retinol 50C"

5 " available from E.I. DuPont de Nemour Company, Inc., Wilmington, DE under the
tradename, "GlyPure 70%";
" available from Hoffman-Laroche, Inc. , Nutley, NJ

10 Example 23: Anti-acne agent - lipid Formulations

The below formulations are prepared in accordance with the procedure set forth in
Example 22. When these formulations are topically applied to the skin, the symptoms of
acne are improved.

15

Table 6

Components	Concentration (weight %)			
	Ex 1	Ex 2	Ex 3	Ranges Ex 4
Retinol	0.05	0	0.05	0-2
Benzoyl Peroxide*	0	2	2	0-10
Elubiol**	0.1	0.1	0.1	0.001-2
Salicylic acid***	2	0	0	0-10
Ethanol	60	40	20	20-80
1,3-butylene glycol	12.5	20	20	5-20
Propylene Glycol	12.5	20	20	1-40
Glyceryl Distearate	2	0	0	0.0-5
Cholesterol	0	0	0.5	0-1
Glyceryl Dilaurate	0	0	1	0-5
Laureth-9	2	0	1	0-5
Polyoxyethylene-10-stearyl ether (Brig 76)	1	5	2.5	0-5
Fragrance	0.25	0.25	0.25	0-0.5
Polyacrylamine, Laueth-7, and C13-14 Isoparaffin (Sepigel 305)	0	0	3	0-5
Polyoxypropylene-polyoxyethylene block polymers (Pluronic F-127)	0	5	0	1-20
Water	q.s. to 100%	q.s. to 100%	q.s. to 100%	q.s. to 100%

* available from Alzo Inc., Matawan, NJ

** available from Janssen Pharmaceutica N.V., Beerse, Belgium under the tradename,
"Elubiol";

20 *** available from NIPA Laboratories Inc., Great Britain, UK

25 The below formulations are prepared in accordance with the procedure set forth in
Example 22. When these formulations are topically applied to the skin, the pigmentation in
the skin is reduced.

5

Table 7

Components	Concentration (weight %)			
	Ex 1	Ex 2	Ex 3	Ranges Ex 4
Retinol	0.05	0	0.05	0-2
Kojic acid*	0	1	1	0-10
Transexamic acid**	0.05	0.05	0.05	0-5
Hydroquinone***	2.0	0	0	0-10
Ethanol	60	40	20	20-80
1,3-butyleneglycol	12.5	20	20	5-20
Propylene Glycol	12.5	20	20	1-40
Glyceryl Distearate	2	0	0	0.0-5
Cholesterol	0	0	0.5	0-1
Glyceryl Dilaurate	0	0	1	0-5
Laureth-9	2	0	1	0-5
Polyoxyethylene-10-stearyl ether (Brig 76)	1	5	2.5	0-5
Fragrance	0.25	0.25	0.25	0-0.5
Polyacrylamine, Laueth-7, and C13-14 Isoparaffin (Sepigel 305)	0	0	3	0-5
Polyoxypropylene-polyoxyethylene block polymers (Pluronic F-127)	0	5	0	1-20
Water	q.s. to 100%	q.s. to 100%	q.s. to 100%	q.s. to 100%

* available from Sino Lion, New York, NY under the tradename, "Kojic Acid SL";

** available from Sigma Chemical Co., St. Louis, MO

*** available from Eastern Company, Kingsport, TN

10

Example 25: Hair Growth Inhibiting Agent – Lipid Formulations

The below formulations are prepared in accordance with the procedure set forth in Example 22. When these formulations are topically applied to the skin, hair growth is inhibited.

15

Table 8

Components	Concentration (weight %)			
	Ex 1	Ex 2	Ex 3	Ranges Ex 4
Retinol	0.15	0.15	0.15	0-2
Betamethasone*	0	0	0.05	0-1
Ethanol	60	40	20	20-80
1,3-butyleneglycol	12.5	20	20	5-20
Propylene Glycol	12.5	20	20	1-40
Glyceryl Distearate	2	0	0	0.0-5
Cholesterol	0	0	0.5	0-1
Glyceryl Dilaurate	0	0	1	0-5

Laureth-9	2	0	1	0-5
Polyoxyethylene-10-stearyl ether (Brig 76)	1	5	2.5	0-5
Fragrance	0.25	0.25	0.25	0-0.5
Polyacrylamine, Laueth-7, and C13-14 Isoparaffin (Sepigel 305)	0	0	3	0-5
Polyoxypropylene-polyoxyethylene block polymers (Pluronic F-127)	0	5	0	1-20
water	q.s. to 100%	q.s. to 100%	q.s. to 100%	q.s. to 100%

5 * available from Sigma Chemical Co., St. Louis, MO

Example 26: Preparation of Elubial Gels

10 Both 1 g of Pemulen TR1 (Acrylates/C10-30 Alkyl Acrylate Crosspolymer, BF Goodrich Specialty Chemicals, Cleveland, OH) and 0.2 g of Natrosol 250 HX (Hydroxyethylcellulose, Hercules, Wilmington, DE) were suspended in 50 ml of distilled water. The resulting suspension was stirred at room temperature until a homogeneous gel was formed ("Phase 1"). Next, 1 g of panthenol (BASF Co, Parasipany, NJ), 1 g of Vitamin E acetate (BASF Co., Parasipany, NJ), 0.1 g of elubiol (Janssen Research Foundation, Beerse, Belgium), 12 g of ethanol, 3 g of Propylene Glycol (Spectrum Quality Products, Inc, Gardena, CA), 0.5 g of farnesol (Roche Vitamins & Fine Chemicals, Nutley, NJ), 2 g of hamamelis virginiana (Florasynth, Milan, Italy), 0.25 g of bisabolol (BASF Co, Parasipany, NJ), 0.25 g of phytantriol (Roche Vitamins & Fine Chemicals, Nutley, NJ), and 4 g of Arlamol HD (isohexadecane, ICI surfactant, Wilmington, DE) were all mixed together to form Phase 2. Next, 50 g of Phase 1 was mixed with 24.1 g of Phase 2 to form Phase 3. Then, 12 g of Propylene Glycol, 5 g of isopropyl myristate (Spectrum Quality Products, Inc, Gardena, CA), 2 g of ethanol, and 6 g of distilled water were mixed into Phase 3 to form Phase 4. Then, 1.5 ml of 20% NaOH was added to Phase 4 under stirring to form a gel. Lastly, 0.35 ml of Tween 20 (polysorbate 20, ICI surfactant, Wilmington, DE) was added and mixed well into 40 g of the gel.

30 The below formulations are prepared in accordance with the procedure set forth in Example 26. When these formulations are topically applied to the skin, the sebum production is inhibited and the symptoms of acne are improved.

5

Table 9

Component	Concentration (%)			
	E X 1	E X 2	E X 3	Ranges E X 4
Hydroxyethylcellulose	0.2	0.2	0.2	0 - 2
Acrylates/C10-30 Alkyl Acrylate Crosspolymer	1	1	1	0.2 - 3
Ethanol	12	12	12	5 - 30
Elubiol	0.1	0.1	0.1	0.02 - 1
Farnesol	0.5	0.5	0.5	0 - 1
Propylene Glycol	3	12	12	1 - 20
Panthenol	1.3	1.3	1.3	0 - 5
Hamamelis Virginiana	2	2	2	0 - 5
Fragrance	0.5	0.5	0.5	0 - 1
Isohexadecane	4	4	4	0 - 10
Tocopheryl Acetate	1	1	1	0 - 2
Bisabolol	0.25	0.25	0.25	0 - 1
Phytantriol	0.25	0.25	0.25	0 - 2
Sodium Hydroxide	0.35	0.35	0.35	0.2 - 0.5
Polysorbate 20	1		1	0 - 3
Isopropyl myristate		5	5	0 - 15
Polyoxyethylene-10-staryl ether	2		1	0 - 5
Polyoxyethylene-2-cetyl ether			1	0 - 5
DI Water	q.s. to 100%	q.s. to 100%	q.s. to 100%	q.s. to 100%

10

It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.

What is claimed is:

CLAIMS

1. A composition for enhancing the topical application of benefit agents comprising, based upon the total weight of the composition,:

10 A. from about 1 percent to about 10 percent of a nonionic lipid selected from the group consisting of:

i. glyceryl monoesters having a fatty acid chain containing from about 3 to about 50 carbon atoms;

15 ii. glyceryl diesters having a fatty acid chain containing from about 5 carbon atoms to about 25 carbon atoms;

iii. alkoxylated alcohols alkoxylated with ethylene oxide or propylene oxide;

iv. alkoxylated alkyl phenols alkoxylated with ethylene oxide or propylene oxide;

v. alkoxylated acids alkoxylated with ethylene oxide or propylene oxide;

20 vi. alkoxylated amides alkoxylated with ethylene oxide or propylene oxide;

vii. alkoxylated sugar derivatives alkoxylated with ethylene oxide or propylene oxide;

viii. alkoxylated derivatives of natural oils or waxes alkoxylated with ethylene oxide or propylene oxide;

25 ix. polyoxyethylene polyoxypropylene block copolymers alkoxylated with ethylene oxide or propylene oxide;

x. polyoxyethylene fatty ethers having a fatty acid chain containing from about 10 carbon atoms to about 18 carbon atoms;

xi. steroids;

30 xii. fatty acid esters of alcohols where the fatty acid is straight or branched chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or branched chain having 1 to 10 carbon atoms; and

xiii. mixtures thereof;

B. from about 74 percent to about 98 percent of a vehicle solution comprised of:

35 1) a first vehicle component comprised of water or a mixture of water and a hydrophilic organic solvent;

40 2) a second vehicle component comprised of an alcohol, a polyol, or mixtures thereof; and

C. an effective amount of the benefit agent.

5 2. The composition of claim 1 wherein the non-ionic lipid is selected from the group consisting of:

- i. alkoxylated alcohols alkoxylated with ethylene oxide or propylene oxide;
- ii. alkoxylated alkyl phenols alkoxylated with ethylene oxide or propylene oxide;
- 10 iii. alkoxylated acids alkoxylated with ethylene oxide or propylene oxide;
- iv. alkoxylated amides alkoxylated with ethylene oxide or propylene oxide;
- v. alkoxylated sugar derivatives alkoxylated with ethylene oxide or propylene oxide;
- 15 vi. alkoxylated derivatives of natural oils or waxes alkoxylated with ethylene oxide or propylene oxide;
- vii. fatty acid esters of alcohols where the fatty acid is straight or branched chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or branched chain having 1 to 10 carbon atoms; and
- viii. mixtures thereof.

20 3. The composition of claim 2 wherein said nonionic lipid is selected from the group consisting of polyoxyethylene ether fatty acids, glycerol diesters, a fatty acid esters of an alcohol, and mixtures thereof.

25 4. The composition of claim 3 wherein said nonionic lipid is selected from the group consisting of polyoxyethylene stearyl ether having from about 5 to about 10 oxyethylene units, a polyoxyethylene myristyl ether having from about 5 to about 10 oxyethylene units, a polyoxyethylene lauryl ether having from about 5 to about 10 oxyethylene units, a polyoxyethylene cetyl ether having from about 5 to about 10 oxyethylene units, isopropyl myristate, and mixtures thereof.

30 5. The composition of claim 4 wherein the first vehicle component is water and the second vehicle component is a mixture of an alkanol and a polyol.

6. The composition of claim 5 wherein the polyol is propylene glycol and the alkanol is ethanol.

7. The composition of claim 6 wherein the water is present in an amount, based upon the total weight of the vehicle solution, of from about 5 percent to about 30 percent.

5

8. The composition of claim 6 wherein the vehicle solution contains water, ethanol, and polyethylene glycol in a ratio of about 1 to about 4 : about 2 to about 3 : and about 1 to about 4, respectively.

10

9. The composition of claim 1 wherein said benefit agent is minoxidil.

15

10. The composition of claim 6 wherein said benefit agent is minoxidil.

20

11. The composition of claim 9 wherein said composition further comprises a member selected from the group consisting of finasteride, lactic acid, ketoconazole, sodium sulfate, and mixtures thereof.

25

12. The composition of claim 10 wherein said composition further comprises a member selected from the group consisting of finasteride, lactic acid, ketoconazole, sodium sulfate, and mixtures thereof

30

13. The composition of claim 1 wherein said benefit agent is elubial.

35

14. The composition of claim 6 wherein said benefit agent is elubial.

40

15. The composition of claim 1 wherein said benefit agent is retinol.

45

16. The composition of claim 6 wherein said benefit agent is retinol.

50

17. An article of manufacture comprising the composition of claim 1.

55

18. The article of manufacture of claim 17 wherein the article is selected from the group consisting of a lotion, cream, ointment, mousse, bath, spray, aerosol, skin patch, gel, soap, tonic, toner, and shampoo.

60

19. A method for enhancing the topical application of a benefit agent which comprises topically administering to a human or animal a composition of claim 1.

5 20. A method for treating hair loss comprising topically administering to a human or animal at a desired area for treating hair loss a composition of claim 1, wherein said benefit agent is selected from the group consisting of minoxidil, N"-cyano-N-(tert-pentyl)-N'-3-pyridinyl-guanidine, diazoxide, vitamin E, vitamin C, vitamin E acetate, vitamin C palmitate; erythropoietin; prostaglandin E1, prostaglandin F2-alpha, oleic acid, heat shock protein 27, 10 heat shock protein 72, verapamil HCL, nifedipine, diltiazemamiloride, cyclosporin, Fk-506; finasteride, 17-beta estradiol, EGF, FGF, benoxaprofen, tretinoin, IL-6, IL-1alpha, and IL-1beta ICAM, betametasone, aloe, clove, ginseng, rehmannia, swertia, sweet orange, zanthoxylum, elubiol, ketoconazole, zinc pyrithione, streptomycin, cycloheximide, and mixtures thereof.

15 21. A method for treating or minimizing the effects of aging comprising topically administering to a human or animal at a desired area a composition of claim 1, wherein said benefit agent is selected from the group consisting of sunscreens, retinoids and derivatives thereof, vitamins and derivatives thereof, antioxidants, hydroxy acids, botanical extracts, and mixtures thereof.

20 22. A method for treating acne comprising topically administering to a human or animal at a desired area a composition of claim 1, wherein said benefit agent is selected from the group consisting of imidazoles, retinoids, salicylic acid, benzoyl peroxide, antibiotics, antiandrogens, 5-alpha-reductase isotypes, anti-inflammatory agents, botanical extracts, and mixtures thereof.

25 23. A method for depigmenting skin comprising topically administering to a human or animal at a desired area a composition of claim 1, wherein said benefit agent is selected from the group consisting of retinoids and derivatives thereof, kojic acid and its derivatives, hydroquinone and derivatives thereof, tranexamic acid, vitamins, azelaic acid, botanical extracts, and mixtures thereof.

30 24. A method for treating the diseases of dandruff, seborrheic dermatitis, and psoriasis comprising topically administering to a human or animal at a desired area a composition of claim 1, wherein said benefit agent is selected from the group consisting of zinc pyrithione, selenium sulfide, sulfur, sulfonated shale oil, salicylic acid, coal tar, povidone-iodine, imidazoles, piroctone olamine, selenium

5 sulfide, ciclopirox olamine, anti-psoriasis agents, vitamin A derivatives, corticosteroids, and mixtures thereof.

25. A topical delivery system for active agents comprising, based upon the total weight of the delivery system,

10 A. from about 0.5 percent to about 10 percent of a nonionic lipid selected from the group consisting of:

- i. glyceryl monoesters having a fatty acid chain containing from about 3 to about 50 carbon atoms;
- ii. glyceryl diesters having a fatty acid chain containing from about 5 carbon atoms to about 25 carbon atoms;
- iii. alkoxylation alcohols alkoxylated with ethylene oxide or propylene oxide;
- iv. alkoxylation alkyl phenols alkoxylated with ethylene oxide or propylene oxide;

15 v. alkoxylation acids alkoxylated with ethylene oxide or propylene oxide;

20 vi. alkoxylation amides alkoxylated with ethylene oxide or propylene oxide;

vii. alkoxylation sugar derivatives alkoxylated with ethylene oxide or propylene oxide;

viii. alkoxylation derivatives of natural oils or waxes alkoxylated with ethylene oxide or propylene oxide;

25 ix. polyoxyethylene polyoxypropylene block copolymers alkoxylated with ethylene oxide or propylene oxide;

x. polyoxyethylene ether fatty acids having a fatty acid chain containing from about 10 carbon atoms to about 18 carbon atoms;

30 xi. steroids;

xii. fatty acid esters of alcohols where the fatty acid is straight or branched chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or branched chain having 1 to 10 carbon atoms; and

xiii. mixtures thereof;


B. from about 74 percent to about 99.5 percent of a vehicle solution comprised of:

35 1) a first vehicle component comprising at least one of a water miscible organic alcohol, a water miscible organic polyhydrophobic compound, and

2) a second vehicle component comprised of an alcohol, a polyol, or mixtures thereof.

1/9


FIG. 1A



SUBSTITUTE SHEET (RULE 26)

2/9


FIG. 1B



SUBSTITUTE SHEET (RULE 26)

3/9


FIG. 1C



SUBSTITUTE SHEET (RULE 26)

4/9

FIG. 1D



SUBSTITUTE SHEET (RULE 26)

FIG. 1F





FIG. 1E



SUBSTITUTE SHEET (RULE 26)

6/9

FIG. 1H





FIG. 1G



SUBSTITUTE SHEET (RULE 26)

7/9

FIG. 1J







FIG. 1I



SUBSTITUTE SHEET (RULE 26)

8/9


FIG. 1K



SUBSTITUTE SHEET (RULE 26)

9/9

FIG. 1L



SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 7/06, 7/48, 47/10, 47/14, 47/44, A61P 17/14, 17/10, A61K 47/34		A3	(11) International Publication Number: WO 00/07627
			(43) International Publication Date: 17 February 2000 (17.02.00)
<p>(21) International Application Number: PCT/US99/17387</p> <p>(22) International Filing Date: 2 August 1999 (02.08.99)</p> <p>(30) Priority Data: 60/095,289 4 August 1998 (04.08.98) US 09/363,412 23 July 1999 (23.07.99) US </p> <p>(71) Applicant (<i>for all designated States except US</i>): JOHNSON & JOHNSON CONSUMER COMPANIES, INC. [US/US]; Grandview Road, Skillman, NJ 08558 (US)</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): NIEMIEC, Susan, M. [US/US]; 1808 Waterford Road, Yardley, PA 19067 (US). WANG, Jonas, C., T. [US/US]; 23 Ellsworth Drive, Robbinsville, NJ 08691 (US). WISNIEWSKI, Stephen, J. [US/US]; 6820 Pt. Pleasant Pike, Doylestown, PA 18901 (US). STENN, Kurt, S. [US/US]; 47 Bayard Lane, Princeton, NJ 08540 (US). LU, Gwang, Wei [CN/US]; 10 Heather Court, Plainsboro, NJ 08536 (US).</p> <p>(74) Agents: CIAMPORCERO, Audley, A. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).</p>			
<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> <p>(88) Date of publication of the international search report: 17 August 2000 (17.08.00)</p>			
<p>(54) Title: TOPICAL DELIVERY SYSTEMS FOR ACTIVE AGENTS</p> <p>(57) Abstract</p> <p>This invention relates to a method for enhancing the transmembrane penetration of benefit agents using a certain non-ionic lipid/surfactant-containing formulation as an enhancing agent, and the compositions used therein. Various active agents, such as anti-dandruff agents, hair growth agents, hair inhibitor agents, anti-acne agents, anti-aging agents, depilatory agents, and depigmentation agents, may be effectively delivered into the skin, hair follicles and sebaceous glands using the compositions of the present invention.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BI	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BR	Bolivia	GR	Greece	ML	Mali	TK	Turkmenistan
BG	Bulgaria	HU	Hungary	MN	Mongolia	TI	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/17387

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	A61K7/06	A61K7/48	A61K47/10	A61K47/14	A61K47/44
	A61P17/14	A61P17/10	A61K47/34		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 10231 A (THERATECH INC) 25 June 1992 (1992-06-25) page 5 -page 6, line 28 page 10, line 25 -page 12, line 22 claims 1-3,12-14,16; figures; examples ---	1,5, 17-19
X	DATABASE WPI Section Ch, Week 199721 Derwent Publications Ltd., London, GB; Class B05, AN 1997-231136 XP002131769 & JP 09 071513 A (TAISHO PHARM CO LTD), 18 March 1997 (1997-03-18) abstract ---	1,5-7,9, 10,17-19

 Further documents are listed in the continuation of box C Patent family members are listed in annex

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

Document defining the general state of the art which is not considered to be of particular relevance; the document may be later than the priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 February 2000

Date of mailing of the international search report

14.06.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

Internatinal Application No
PCT/US 99/17387

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 21262 A (ALZA CORP) 29 September 1994 (1994-09-29) page 5, line 25 -page 6, line 10 claims 1-9; examples 5,7,8 ---	1,5, 17-19
X	EP 0 431 942 A (SANSHO CO ;TAKASAGO PERFUMERY CO LTD (JP)) 12 June 1991 (1991-06-12) example 3 ---	1,17-19
A	WO 88 01863 A (UPJOHN CO) 24 March 1988 (1988-03-24) cited in the application page 2 -page 6, line 17 claims; examples -----	1,5-10, 17-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/17387

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos. .

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. .
see additional sheet, subject 1.

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, a glyceryl monoester having a fatty acid chain containing from about 3 to about 50 carbon atoms, or a mixture comprising it.

2. Claims: 1, 3, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, a glyceryl diester having a fatty acid chain containing from about 5 carbon atoms to about 25 carbon atoms, or a mixture comprising it.

3. Claims: 1, 2, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, an alkoxylated alcohol alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

4. Claims: 1, 2, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, an alkoxylated alkyl phenol alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

5. Claims: 1, 2, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, an alkoxylated acid alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

6. Claims: 1, 2, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, an alkoxylated amide alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

7. Claims: 1, 2, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, an alkoxylated sugar derivative alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1, 2, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, an alkoxylated derivative of natural oils and waxes alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

9. Claims: 1, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, a polyoxyethylene polyoxypropylene block copolymer alkoxylated with ethylene oxide or propylene oxide, or a mixture comprising it.

10. Claims: 1, 3-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, a polyoxyethylene fatty ether having a fatty acid chain containing from about 10 carbon atoms to about 18 carbon atoms, or a mixture comprising it.

11. Claims: 1, 5-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, a steroid, or a mixture comprising it.

12. Claims: 1-19 (all partially)

A composition for enhancing the topical application of benefit agents comprising, as a nonionic lipid, a fatty acid ester or an alcohol where the fatty acid is straight or branched chain having from about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or branched chain having 1 to 10 carbon atoms, or a mixture comprising it.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No
PCT/US 99/17387

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9210231	A 25-06-1992	US 5164190 A		17-11-1992
		US 5152997 A		06-10-1992
		AU 651165 B		14-07-1994
		AU 9175791 A		08-07-1992
		CA 2098195 A,C		11-06-1992
		EP 0562041 A		29-09-1993
		JP 6503252 T		14-04-1994
		PT 99751 A,B		31-01-1994
		ZA 9109761 A		28-10-1992
JP 9071513	A 18-03-1997	NONE		
WO 9421262	A 29-09-1994	AU 6410494 A		11-10-1994
EP 0431942	A 12-06-1991	JP 3236317 A		22-10-1991
		CA 2031243 A		07-06-1991
		DE 69007592 D		28-04-1994
		DE 69007592 T		13-10-1994
		US 5246949 A		21-09-1993
WO 8801863	A 24-03-1988	AU 8025787 A		07-04-1988

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 February 2000 (17.02.2000)

PCT

(10) International Publication Number
WO 00/07627 A3(51) International Patent Classification²: A61K 7/06, 7/48, 47/10, 47/14, 47/44, A61P 17/14, 17/10, A61K 47/34

(81) Designated States (national): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US99/17387

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 2 August 1999 (02.08.1999)

(25) Filing Language: English

Published:

— With international search report.

(26) Publication Language: English

(88) Date of publication of the international search report:
17 August 2000

(30) Priority Data:

60/095,289 4 August 1998 (04.08.1998) US
09/360,412 23 July 1999 (23.07.1999) US(48) Date of publication of this corrected version:
8 February 2001(71) Applicant (for all designated States except US): JOHN-
SON & JOHNSON CONSUMER COMPANIES, INC.
[US/US]: Grandview Road, Skillman, NJ 08558 (US).(15) Information about Correction:
see PCT Gazette No. 06/2001 of 8 February 2001, Section
II

(72) Inventors: and

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(73) Inventors/Applicants (for US only): NIEMIEC, Susan,
M. [US/US]: 1808 Waterford Road, Yardley, PA 19067
(US). WANG, Jonas, C., T. [US/US]: 23 Ellsworth Drive,
Robbinsville, NJ 08691 (US). WISNIEWSKI, Stephen,
J. [US/US]: 6820 Pt. Pleasant Pike, Doylestown, PA
18901 (US). STENN, Kurt, S. [US/US]: 47 Bayard Lane,
Princeton, NJ 08540 (US). LU, Gwang, Wei [CN/US]: 10
Heather Court, Plainsboro, NJ 08536 (US).(74) Agents: CIAMPORCERO, Audley, A. et al.: Johnson &
Johnson, One Johnson & Johnson Plaza, New Brunswick,
NJ 08933-7003 (US).

WO 00/07627 A3

(54) Title: TOPICAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

(57) Abstract: This invention relates to a method for enhancing the transmembrane penetration of benefit agents using a certain non-ionic lipid/surfactant-containing formulation as an enhancing agent, and the compositions used therein. Various active agents, such as anti-dandruff agents, hair growth agents, hair inhibitor agents, anti-acne agents, anti-aging agents, depilatory agents, and depigmentation agents, may be effectively delivered into the skin, hair follicles and sebaceous glands using the compositions of the present invention.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)